var title_f13_13_13520="HSG arcuate ut intravasation";
var content_f13_13_13520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61897&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Hysterosalpingogram showing an arcuate uterus, absent left tube, and intravasation of dye in the uterine veins on the right obscuring the status of the right tube",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 331px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Baramki, TA. Hysterosalpingography. Fertil Steril 2005; 83:1595. Copyright &copy; 2005 Elsevier Science, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13520=[""].join("\n");
var outline_f13_13_13520=null;
var title_f13_13_13521="Phonocardiogram calcific AS 3rd left ICS";
var content_f13_13_13521=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/67896/asc3lics_conv.mp4?title=Phonocardiogram+calcific+AS+3rd+left+ICS+\" style=\"width:396px;height:488px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phonocardiogram showing paradoxical splitting of S2 in aortic stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 403px; height: 253px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram and phonocardiogram of aortic stenosis due to valvular calcification as heard at the third left intercostal space. S1 (mitral and tricuspid valve closure) is followed by a mild systolic ejection murmur of aortic stenosis. In contrast to normal, aortic valve closure is very delayed and it occurs after closure of the pulmonic valve, accounting for the paradoxical splitting (S2 becomes single with inspiration).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13521=[""].join("\n");
var outline_f13_13_13521=null;
var title_f13_13_13522="TMEP III";
var content_f13_13_13522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F59118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F59118&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Telangiectasia macularis eruptive perstants (TMEP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Cem Akin, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13522=[""].join("\n");
var outline_f13_13_13522=null;
var title_f13_13_13523="Femoral hernia";
var content_f13_13_13523=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Femoral hernia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this sagittal section, a femoral hernia protrudes through the femoral ring posterior to the inguinal canal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from O Rahilly. Abdominal walls. In: Basic Human Anatomy, W.B. Saunders Company, Philadelphia 1983. p. 230.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13523=[""].join("\n");
var outline_f13_13_13523=null;
var title_f13_13_13524="RR of HF amlo vs chlor ALLHAT";
var content_f13_13_13524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F62097%7ENEPH%2F52700%7ENEPH%2F70843%7ENEPH%2F50881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F62097%7ENEPH%2F52700%7ENEPH%2F70843%7ENEPH%2F50881&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart failure with amlodipine versus chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of heart failure with amlodipine. Graph, with natural logarithmic scale, showing the relative risk of heart failure in all studied patients (total) and prespecified subgroups given either amlodipine or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, amlodipine increased the risk of heart failure in total and in all specific subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Combined cardiovascular disease outcomes with lisinopril vs chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 333px; background-image: url(data:image/gif;base64,R0lGODlhBwJNAcQAAP///wAAAICAgEBAQMDAwKCgoPDw8DAwMBAQENDQ0HBwcODg4FBQUGBgYCAgILCwsJCQkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAHAk0BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ1aCwShCSkJAwUsBQOjNQoDJ6WnVKGzBnoGs6Geuk0CAb4BBygEAQIoAa4ABAILNgXFJsPPU7++BHrD1LvaSb0CBgcB1gYCAwwPycTJDAMDEAAFAQ7LygsPy+/e7+zuJMoJBQSciXiwrkGodPZWPakW6ta6dgASCLDmDwBBiPgWQFhgoNUAaVmGHZilr9w5CM8E/7jrOKDBKgEFJEZsUC7WtpskuhlwEIDZAQQCwCWIBkBAA3IBCigIgEBVr4AB3CFwAGCpAgZRczIlNiDAuwAMBISNNqyBFF8C0hY92rXAArAAsNYDaxVAVwThHABVQHXLMHkw4yoQwHNBgwAJEgQw+zMoAmZbewIzygCnZRG9fp1S/PHwxHQGIDAAV+wY5nAGEBxQXGxqWtMjep2z6xXC5FPDFKiuFYWa19Cj03VN7QprrZ+0eSNAcJSZX2quFpDjeVCBbQKKFVjMCkyEYgfWeV++2asBXnfDPqY9WOwnBNulkT0FcPgwZMCBY4cT0RVz1wAKDLMcAuIt5NUI7sH31f9hp/RH24PeMcDTY88hA8ACqhVwmDUOHHAAVUQRBZtFA+AVzHjkEYPNKMsBBAFA6cRDwFKlOUCAdPs94AsyWE0kkH7WPAhBgPAwkJttlbHmhC8kyEgjAAb4QiAA8OlYmYN2AdSVQlikN8IwRnZlzVLpADAVAViNAhsBDTxAwHIopljMUgcYkABW8biZDjzHpJOZRPsBwFMsBpjHFEjzPfgAT2DdIlxUtjnHBJMj8NnVM/WNoFujEMbliwM2hTQifUyBY81bPXkHDqgiwLYAOMBwGeesWjBgFq245goIA5Lq6uuvwAYr7LDEFmtsDPYUwNtQtFChEUwG3NIsEEOJl4r/rBGZskMr+mBrxLPK2qUdCQOMC0O5K8BSlYUicHvsIYeBc+J/1Swxqgh87ohNvUCI+eU9JUgXZA4CJZpEvqbdey8KiS5cAlE/joDlu4MoFgyDtEHQUD8TMcDAKmiWW4szGjFTwDoKREuOORcK8EArxcAjj6RvIWCNTABQGoS/ItBjUUE3ToQPQR+LAIFJ+E7U0sjLbFRwoEjUfHN8RzdQC2wX8eNPAaksdsoxVY/MDssQP/NAOTwNtI7WLtM0W8gpUwyHSEU9eoC2Wn0Ep5VLXbmVMmARRkBjQmFTYlJLNaWQbeaOoHO/UD9VpFifFdNVh/FUBSBW53TVQN+04UVA/38GH8F4Cb58uFjOrvANYN14SQiMdqnzZBYDgxVGVH86HkCYV65r10tTvsyFO1xyv8GT6nMKsOlsp40ZTo+/JyfCVCI42pmKCMXIbt0gtXrgzpGHY5vvuD0qAjhmBhOl3+t7NRx/XpVuRDeouxKlK6YZBwBysoleq/RnGukMgDq784pcHuQ/AO5nKWgiRvWS5waNiAZq4NOKNZ5yqbRYbnwjSo8H2YOO+JQAHhZyzuN+wLO6bfA/AVLfg2BjGgf1B0ukw6ARUDgCyCAjYa6wYf0C1bAfDgBDB9BQOBIIoRseKIcbDEcH1ULBNripFycCz6YGVjcIPABOSCLAA8yCJf+saMxILSLAi0IUIxv1iicfWYejUEO+oyzjKUOCipFk2B/O9cIdYkJSp6C4BDiKhX9GZB2ViGElF55GaDQcAJhGt0T1dWNRtWEkXOaDR7CI8VZVXMNdrCYCPLFKKzxxwEsYBb/sGcoBC7jTp/RUDKL8iQQLMKXGqMHFHtArHE/BZKOY+CADYAUB47rcMWqBwyH28lu6VKQiYbMpBtQiUQvgSWUiSSrVVPKDULpc2qoSu2vuh5OsDGUf7FeJianznWNgJyXcCc962vOe+MynPvfJz37685+LyAVAB5pPKhL0oPA0KEIXSkGFMvShx3IoRCcqLIlS9KK6sihGNxonjXL/9KM48ShIR6oLkZL0pJowqEBXsFKUujQRKzUpZsL30poiwqDjwMuheCNTm76AWbPwVrrwZgWhRoRjoRrBncTjrdAATBlpSapSSVECe1hDKZGg4jd8A4xr0tSnNPilw4hyArI6Cx4nWABaezaSo5hAFd5xVwnasahrGgQ7JlDr+HC5Vv5MZBVGCujAqJgZrhajp2BlwVDqg9esieAwHykJ2coki16U1bLtOsWrHgZKDX0PSn1pU1G+2jPMPsy0GgrYZwthUHKkRadcBUpkE5sD/G3neNpZVXFy1xOzVmGvqJNYkIAboH58dnQzLYoDPlKgJqVgfLYqx8AG0FzWSsO1/4XlKldIS9sY2LaBCCihCAyIQMr+9rnCbdVcH3Zc+RSDGYXSjkcUAlzn8scdCXAAT59JiNY+Q7u/GG13cWBbIYoXiUok4RXq67gRBNZM6zWuCUqBGX70bLU5Qy9/giRJzPB3EP69HoDDi9gBp8C2VYILmPQUpm9iYXzSsS+VtEOQEjSgV8jtWSymtJpkYKZxMo5xg41mltTw5saKCHHdtHtY7pq4BbYlJ6dC101T+VYKXdPWMPDVFW0ZgB09JkHEFPATuJIDXx4aV1AOYE0TZDl9XD5GLMiMt28sQslb9U2dBPxkXex5CvlJhJKhJACdAoWnTu5zJR7wZygU4ERJlv9GS1MwaUVbeg0lvrSm45DpTXuaDZX+tKhHTepSm/rUPgg1qlcdz0Sz+tVb6DSsZx0FWdP61kywNa53fQRd8/rXPYipqx/2YWAbWwaDdoGvj81sPvM5p1LKhwmW/WRp/UAiQgPFLHoVBKE6I0jS8eCE2+xUbl/oPbzBxYeNqpBwqwWrhghxnqnR6NgMW9Rkgp4NEuCcwyz3sNS4dw30egKjDI4iI6k0XO3iRf3i0gEPKIDDPWjaHvaVr+M7uEAf3N/rApzJ0xa4pxkFyrPZsWcoq26cr4q809y1V/YwmbRtALgTHMBk2skxNG61k8fqe0iPDVVqT8vgml9YtfFWDzn/9DZiiqdltrDWEQTwUoveVc91lcFloZHpHKzcJYr/LhA8pNKXHDD4QMh9U0u4XdxkuJcEQHd2asytXmN8qSlI5o/K/YBdigMYLU6H+qvtg7GuMKOPEhynd3wRLolBKnNK+V3jUnMAqe/g7EePFpUgzZ8vvX0EO1EAma97q/kO+QTj0zwEIC20jpvg7/WldnejdIzlNVF+ElRooVwjHqxY43FeIkG8ArD3GTA4vOoILrmUKh8LfykBooUShexOfeUXpdh8UKk1YOsb5OdE5Je2jR3xkgAaYXKRRhqjCUJjO5OBxTbFOQpPwoeNrOsAxs9gmXUiUovB2VhSPDYKAUEC//kVG6CEej0EEuOTAP0HaXkHYh63ZIYVcrMGDrxhFV8WD+P0Oy0HDQ+2KdRVFHiBTCfAE/rWDF0GZxFxNyHIaAMQZpUiDY92AGqGDDRRNNJHd/ogZ+gQZ9rigmFmZ9Zlb1ACK/RWXbJ3aWoVEKphBFFSdlNQb1AQaBBIhIRmaDP3fcaWADqFg0SgIFXAaMV3MJw3CMIWA6rWbGr4Akm4hm4IZeD3hnLoXXE4h3bIAm14h3qYh3poh3zYh3KYhoA4iIRYiIZ4iEsgiIh4iH+4iMDWiI7Ia5AYibg2iZRIaw6liP2AfZf4ag5VYpbYiWD1iSABbTtlhahmbTOgeSiAbf+nggs62APsBnrOIFUR0WbecQLlRosAM2FphRIKoQyxAG+RVgI4ZYS/8Geh+FH5NgNg0ngj4G+RlV11CAMEl1d99R5sAmR2sQrlt1p05XCvAhDmdo0loAAFsCgIxyb5x4mAQIr6AXLOdmokNwImR0Vw01xjFDvhUiRa8XIkEHP4MIYuYHREZwI11g+dRRPrF1rn0AC2WFoMRoToeCEnsgAYVoVaKGLahXzLuFFSR3Xb4Ttpg3UMUy9exxRgx1xilhXYc38aFhte2C5cpHOel1zItHbVdwLa0mEZpneKMGl9B3tPV420RXhJQRuHp0CJB1z7CBbh0hXvAXm8NXmqYXn/MLmTySB6EXaT7JVciKEP67JwP3kCqbBhdXd9WaV0ROlaqbgjtmdgUwQSz1ggvpczexV80QgMxHd5MSljnSdhJUBhReEOIKSVlfJnD+Z9rfcIBsV91OCRRglW4vdaiGF+aRNG6tdDboILI/N+/SN/5oUOHYgD+CdjQUIAUEgfOGYhA2gmxzEKDIAbZXh6QvZo4gF0CcmaQdlLrQVgKTGZPmWB7QIgGegAG5hOX8JVQQKC1zSC3CgoAXCCNfBmPbiD2hIULygrY1Zmo3Bm75Bm2cMOZFkpKXidwMAO2vFl25k9tTmEG1mEXKWMwvlkS1gATVgET2gFUvgEVHgI8Ah6/4UWbeLxkSfFhb4wk0IAhlQghlj2nvD5Je4ooaL4awZaoaV2oRg6ahq6oZ/WoR66aSAaopc2oiSqaCZ6ok+miSraoi76ojDKUSwao7uWojRqUzZ6oy+VozqKUusxockApD3aZxSnbPU5pDsqbtkzoKeYXLS2MRFxI2vgbY0pjNW1VFO1fijhHM8yi62YgOJGjIKmpPOWjIh2a77gDqhypFBgjjlhECNRFEYCnuTijXJFLg1XC+iojtjIYOaocUHCcTelpNkVcE46a5+iOWWSChAhHS8jeF1ScQiCc3YxG8DFJpXCkCXQc/ShbxJlkByTcd+DkXdWlEwaW0WJpiY4Ff/pYBVmZDh4EZHn9XpHtyhKqik12V6HmiWIeXpq94AhOKbY1ZaQymrHwADLgT+u0QuS1D1sOgSY53bvgI7osnyCKZgGdZZjSV8xqXqsJ6R7EApUBHu7+mrHoCOD0UYeBCO1NJovdgLIhyawuT5c8j026R3Nh2bFN5FlKWONOaYcGVvlaqyuQADjkA49EhCVI15ccJpxcQ77ZyOg1SsPKK06dj2xGZ5j6LBpyYDJ4ICxqJGF+gvBiaYWgj+7dyhs9KxAYJ1btoLsUAsJwIJJ1Z2KUxTIMIPjkp7VKmbn+bLWCYSrIIQwBVXuOZ9niqRX0J9O8J/xdqumeGioqLQNyrT/S/BojPCjBQmuVJtYPNq1G/W1YHtRYju2E1W2ZvtQaJu2C7W2bHtQbvu2AxW3cvtPM1q3eJu3eru3oMa1fDtgdPu394SPftszhSu4AEVY1Ri4iIsiiquLTCq18dm4HPW4m4qMqVMgjAtP1QIlUhqkaeClUOIM1HmLTKWLWzpeKFFs3tKluMQbYjqoAzuyaDG5+LYnKtYdZuCmFjc+2lisC/eNPJmnVQEQldenJ7CnEmsAfFpKh3sHhKV0HgSZvwAUHlSsnqYjrnAYJPY6LOESSXM2KUMTIJNyRVEAYYMEoPov9XWvmIovmkoCnBp97eJ8EqkCaiEdEjteGSkI0et0/7RLstfLsiTFFO2DGP5COBQiTkxxObcFOrWzOknAr7F3gFWRq9DweQugAKSEgClAVD4JlAA7j+IDYLYram0xnVGBFxHxOpbXH0xEPWljGvujBBQ8mA5nrV6Jrc9wCwMAsezArSigrWgZG89bB5ZLAtQrJSf8abaRNqpTGSv7IEw0l9LkMND6l/mFLfb6WYSpEtdqfSdUbyGslkU7u8DZxJ6mGJuUptdjI2lCxeqjmWbBTROcgDK2xSdQsTr3mgHoY2tRfbcphWVcscV4uUirxp52Hi0clisYD7EAwzLEgduUSEfgsgdinQdEnickDWR2s+Cps6XkIbjoszz4sjyrHf+loBrjQrRZ+1VRm4UkTLk2YLW5JquCIFB3S2y0rAMOGgVYW6q9/KEEPMwUtbnGTDHInMwRVczMzFDL/MzEEs3SXFHOXM0ERc3Y/CvavM26ssveHM7iPM5KK4jgvInkPLhO5mvdnM6ud2KwHLmyPMsm5pnt0r8kcKdFRVX2+K9KVcpNlbqj24u+mFer+y/DGJ0RWnA0VaaZa4zXvFCRaQ30hAIVHQW8O159xcGjY7/dGFfgSLwH0HDYktHFOzjncHBuFRdHjMTrTFMBHD7tHCxM8iQO4hHgmww04RL9MQ4e7QTre78YeyGr+b7vEL+g55AzC7/QIKnn6A4VuVkXgs//77jO0muZHRl4EY1QaPEhSykC8qAbIDIZH3FDCGBUTXDDQ92vFxzGRzdaS22xtJpWHMxMwyUxBPkHItV3HtSWA6xpcClDM3I4nsKll5KUVqDWm2cUwNXFGZxcHrN023p6mzo6nXPXHnbIDENT5KrItEUpTMI7YMFouEcu8eCuvfGXoBDXEvOVg5mvURq7lP3Yi2nEms3QJrDEBuzZiVUNT/wgl5SZiwFVhscTaD0peDzbcZFUfOyaO5ax2QNLgvwMQWIUM/Yz0RiyVY2/MJ3GvA1W0DEKPb0qyckUZ+MVf5HXl/yzmfyz7EBTNmtmOSueVMIOpYvJo8xmtcCeQQih/xq52euHuV0F0e5sy0vgtIUgiBYVy0i41WP7y47m349wzhTqzhZ+4erb0hjuTzO94bvQ4R7uCSAe4pww4iSeUg5+4nJj4ip+CSze4pXw4jA+CTI+41mV4jY+zfdG4Tmu40ba4wUlDQw+tbO2Mbeg3R8MZD27Aku+A1TKRVY1bqerpb34bfz8CryY0K98tHqWtGiau9WoMFQ9QD1g0gYXp3bxV29lpyFdV2txcMgb51SiMZ/jvMIsgb5Rsrj2Cwp2NCxzvumbP26pSIahnvt9NBBhGhJRujIQ1P9DqUO3c5n6WfN7Djc3rU1ddE6dkKR6yLotmbsGDFOhI3OyOdOJl/+qY8E5g0xmpEijw9hkBCC6wTqUp94uEK3IFV2C2tY77JVqgXYYptiY4YXBelPqQaw4flJy1iet4T5wQcMJsyOKVMOw4VnHoBi34kMlctwxgOtBhF85HJi9/ta/fnSml5Zz/SVcmdmCdux/l6p7HkS1y03cFFRXjEiaE0PNqoCnreGAOQLxeiUcxkWO/doVBmHJ58EK76/+zmnP8OkDa64FW7t+xB2W3CRtZfG0EXGmsRwPwGg5sxrxYOst4LD65w4QUGRTkt3X6scZe/LTjZo9U3aGDJ8xHfEE+1igcUw7e/GOo1M9HxF40WW3KO2m0Qv2h4KnfCAzG7Ptcjc168n/3omzaEaDquL0J8TePngK2tnfd+7QA07PM27gSoDg73yFBErkOQ7hTxDMt60CPA7kwVLjci9YdX/3eJ/3iRX3er/iyd73HfX3gD8edD/4/iv4hh9SiJ/421D4jM93i//4JRX5kt8Jusb3lb8Juub4md9q6yfPDf5quEAuCq3PK2D6R/DkCH2lAI26Ve7PBHjlQGWwsv20iNzlBG6s1RsLZn/RTZKzkW/mcLpBc/pZwYv64WhXcB4wF9e7MZgWErvrtq8V8qj2pcYkr3JOmkUTIrPxS8NlECEzy/AjG4w0Q+Dol45VP4zuOj3pDelzj47pB5npedUXnd7uTvfpWm2u/5kMAgEDBANADEITNMDAKiIQK0wAxciQvICBIFQmALFoPCKTSlIyQEQBHg4B9aggGKFHbdV5GiK9TeSgUBwYluo1u+1+w5GCFJUauOPzdWoq7v8DBgoOEhYaLt09lZAMFTS8mPQAHDghTAksLro4QQSYASwcrokZeUEVKBQMKByBPbm+EnXFKgzsFJEe5RI4GAlgiQYL+1WV5h0fFQ8vMzc7PwcmAhSwMM4EXC1K9gRcCphp9mACQxPlEiE8jSCkTSYYwWoZ8chCAKSfjIwp5Zb5kpcLaEgZumN48BUhKHAhw4YO1dwhUABIKG0BHlCLFIBApxE2fhUQQMIBgQU9Ev8EOCBR3zMxC0QCYPBghj2SPhyEKtIgZ6wnn9i5izlTgb19oGCay9LLyM6HTt8oxGQwAFJZVZ9izarVUB4G76wlQFDColg0PhqIDQJAKg8vDyhRfaaqhBkCXhIcsJUGr61PRUIWUXBAx7s5RAocOMAKAF+zR+b6s3sY0id/RQwc2KrZ11XMBg+0S3h1M+nSpk9rBq35G+qsCn0IEBsgSGjRrW/jzq370NvaThHvdvjaDQGAwY8jT658OXOoo5tDjy59OvXdw6tjz659O/dD17uDDy9+PPbi5M+jT69+Pfv27t/Djy9/Pv36a8zbz69///nv/P8DGOBx/glYoIEHuvb/HIILMtjgMwQ6GKGEE8IBIYUXYoghQfi1wWGGH4JYH0EWWhWiiSe+N2Jnsd1BW4kojldcGgaUNAgPZqyiRI5v1PLHV0n8aEBIMyGRAAOh/WiEARAIkBMBdfh1RJJSGvHAL4ctlp+KSsKVh2okwhjdHSPYpeAbZa4VZSmwNNGImUosQE0ScYoBAQQojHYLYz2SAYEUaahQ3JSgyIkEnYE1gEJRDBg335YJTRUXmGE2h0dxcQEAwQAyyVKApg34dtamkpqxwCOrpFHCHDAZMAen1EwRJ0wL1MLpEk+ecwImSMjzRAuHPYKEAUs1MNN3uCaBLDppLLCUSfp5uGodshkU/0QflIKXkiUPxEWDDTPdcYAD1RxBiQIriLQIniu0MFsNN0wSBCUJ5LBDDz8EEewoiMjxa2AA9dpTFQI4kEKoSfFTBFBMEOHYf9LaESlV12LLHV1jiYRAZgbIsAjHJuCxQzVoauIIJNZ8jFIK6FqzSaaeEMETvwnP44Bv8bDJhUihGNAAK7XoybBREBygghhXAkiQxE5MWnFyFsWlSSZDqCsomiSbQINdIFM9wNZ1YBEO0xu9kSvCRCTgwKA4FzmEAEX1FMbMMROAV0KNxhdtVdQek07TTh+n7h0ifYuJPVLD8gNJMaSrEUaZqLSCPUAUwBE4JJnkBEoqFcDS3C+VUv9E2oMC0FQR8ki0bFDACJClLkWAjgsSDPhluohVjRipSH8DvpsmLBtgAwKLIY7ERBiDVVYmsi1m5B0OGHtHW0S8NbgakNXlBfYuFGzLY0gJRthajSS2mACJHWk8ZSdovz4KFGOm36NEeHbMl2/2nv8zqm3Fmpa4r0g2LloL/vRnwGH0RivAkV9VPHQfvB0wghJ0Cu8maMELYqWCGNwgB8uhwQ6CMISi+KAIS2hCYhTwhCpc4R9IyMIXvtCBMJwhDWtowxviMIfzedIeeujDHwIxiEIcIhGLaMQjIjGJSlQiBHV4QYgtMYpSnGIPbUHFK2JRiRRzYgddOKAUUseLXDT/kRitA8bplHGMH0pjbtiIGzeqkUJwbM0cUVPHODrojqbRY2n4iEcE+XEzgVzNGf9IKRl2B5HcUaQhG+nIR0IykpKcJCUraclLGnBJTTIe2MBDOu0k4G0yw2SGBuAnm7XiTjXaDr3YtB2ZTORgpIzQsIhQrFY0kTomQ4/XZpkhnbUiL2rKTsDA84NR+jJCwDRCKBZwACJtp5jdaUAhkwkgeqwFbsmoJnKkuZ0G+MuaFALKAd6RuhM0DJra8WZ2wCnODCFGMbIYAgPK153wBS2aJejLO/vpz38CNKACHShBC2rQgyI0oQpdKEMb6tCHQjSiEp0oRStq0YuupzgyWgKf/9RwI0F8FAkdxWhEj6FOeJhtHEfJJRtegjdJkLSkTsiIOlDlshnYogEJyFwDCuDSVpVKADMx1QB0ysxfYMSlPgCaSO71tpg6NBGdaAG3GBCDEUhiCgqwRNpSkg2ROCAdnfCpxmKDEPaVBU1hbV0vejAABHwSqgX1Uho+QjAnSIIAtRDLWsiGJkw8gAHsmOocyKaIxaAJCNQMxQswMUy5HvQOMUBlY+vgsqpWr69YQNMCWFANTFCTCjxBE/tEYqRxISBz4+ImZK2ZiBeMoCMEeEALxEEVKYztF6SFCxY29wC9/oi0aCoDCgLQlmYZt7UKTcQCxGKGu8rgXpRwwLhAMUMuRmEKVkWoXkpGiyk02aAbOHKCXVCp3POiN73qXS972+ve98I3vvKdL33ra9/74je/+t0vf/vr3/8COMACHjCBIxgCADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of CV outcomes with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of combined cardiovascular disease outcomes in all patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of these outcomes in total and in most subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heart failure with lisinopril versus chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 336px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of heart failure with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of heart failure in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of heart failure in total and in all specific subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stroke with lisinopril versus chlorthalidone in ALLHAT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 333px; background-image: url(data:image/gif;base64,R0lGODlhkAFNAcQAAP///4CAgAAAAEBAQMDAwPDw8DAwMKCgoBAQENDQ0HBwcGBgYODg4FBQUCAgILCwsJCQkAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACQAU0BAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJFcBJQEBSkKAywJAwcylZYinJ4mAwpQoKF3BamSZgKwsA8oAwIoAQIEAAwBujGxsru9JwKaT8C5eATIrmWwAAfFIgQNppe1IpkDCwkMtQsHvJYBnryzDAvbCSXP0ZriAAnpDZ7SCQGzS7CVrNUDEPGGEQiw7kE1gNACMIDAoIC2AFqWGagEbcCABrMgQAQQAKBDdSLI3Ys3j1SzIc8g/whYAOCBgAYKXgLABsBBAAUIHCRwIMCAgmUQHSAAoDIcAgMBEAwlkXIlAKAMegZY0ABAsQJHL+kTEKArxwUBaoWT2UAAA5cwBZyqhSCX0JsOIgqwSQ4AzAA80QlIkMCpAQQB/jKw2tasVKoniQAzcKlsV54zbT3N1JZjMqCWDSIooBJsLV8iFl8C2teBAgiXig1AsI4JM84NDHCNjFVT2Ut/aYtQCnZwlmWx3oXlSUmtSgJ9T7kE2FPU3NNaEweBFdPBNa5dIWJD+0C2ZV2Yoy5wigtsV9+h1c4dPfvB6uawiDd5NuIvBJUQo433RBMbzXgN8IQAelYsY8wuRx0wnv8uDhhgQFyYYSaNCO61ZYB0QjxTS1UqNUDAAyxhgws+kI1Y3EayJdOXAQ8QoEBr6UVWFVAELNCiUlYZUNolCBxoBH2hOeDibAXAshlRXKEV2QidEFALjAVO+NRLTiYT02wA5ETNXlYZU+ONS2H4wzMMtOUJXrBUhU0BsjkAGQM8eYhlNHFRmKIBBJJpJlR3riMNLg30ZdKPkokQTTFYjsdSNm01cN0IZc01aJQ+jndUMlGZJUqbpEzIQJ9iIgJBnaGWauoO+Jyq6qqsturqq7AKUsABqU4DShULkVMAA7f2kIAqFUEpSic7ZBKsErkecM0pJJgig7MqjAKAsSRQG+v/CWz2pFZ6sbjmo6HADIBLtz18NsJABIoAjw60fpfEobBoImVo396STJcrYNZus4VeW4JKp+RlVS6UlDAQNYFOU40Cl4gEEWcWeRQWRk/hk84sdCo0QlQI6DKSgT+YO43GBm1DADy0GpQwURflQ6uTC1xC60IMtIsLaEVw7DFExUCwTWrGlIzQQAkccMA39fzzc0UtT5nfRu4FKJnQI4M4QD7UWCMmLmslE6+HJeAiLo5oxVSVAIVFpgBOAPwV2F649AgLAzH1CCPABs+7g8jfRdNAAH9jVkuDc02rVlmzfGN2ZG1V6e4ReDPVE08sSVP2tnG/xJNPAz/o1F15CW6L/0tIQXb5KXHXYtblVWGY6Xu6/G0pgTcbvuVjtjQXj1O79CXueF1Z6fW3I+Zdbw5836wSUp6ILoJ3RwFQpJqSeVeLViLea0TxTGlSpLy2CYDbULjkUzu+3wszAHHOlzUYNre1Tb7wt6MZ6j0HQMYvzrXfXEt2PPMSlqYkrq4MJBm105s7NkbAkGmvf6r7yWz6kztjSIOCSxJB9nBGhAWqC1/4uqBkNhiSe02oGGUygIIINkFbYBCD/cvF/7ITqgNs6RQEQIqlomMZCDwARx36UOUOpJQHdCdLCLAhBGiFQK8JiUA8EVc1FtITDiJvJedR3k/85rwlIQ4XAPlMhzK4pP/zHSGKgAMfvfCFHyWdz0QgLMYyPPQZ543oAZBpo0xiSIAggihU8dnIp2Cho7DNZS6tQZNMpJSASGmikfF5AB8tw6WNRcoBGgGGD1S3j5vhMU2saKEGbVGAsiCAWYO7ChlJiAQGXJI5FlTjtBrVsHvBaZGxBIClZHOiJRVgcPrDyUtqqYv+8UQm/hqBGV3xn2Q683HNaOYzp0nNalrzmtjMpja3yc0xFKyb4BSEV8JJTj+Ms5zozMM508lOOqyznfB8wzvjSU81zLOe+CzDPfPJTzDss58A3cI/A0pQKwy0oAiNwsF+8M2EOpQGB4XoRh5KURgctABJMVIAeHiLieb/4VegEFYLpNUFkY4ARgPpyqQApJVdnYAXqBFFR9JFApPeQ2OGGgY0mEUIJ3nUBNlCBmNWEFE4cDJeJ8BMUgeYhQRYq6bWmgolRDqA1vgUqA54gM9EgJEDHKkETj0eRvA4GKlOhKtW/AP37IUMWPzUBEV9w68UhZyWHEQE4xEX0yimVC0o6Hh/VeZbp7Eojui1BH+sCQ8HYMXApqCQeNqpuo5nzmIA8LIZbSvaMHvZw/KBe6dr21xsowA08Yqpv6Gsk5TpAHFx9CckmOc4GTsCrND0KaoFS2imcaABcFStluVs8DTrVuF2xbN74F78cqNUXqyPhYMtkGoPNJgCLICn/xoM21tnCxrdTssiVqXsWSIrmdWGJK19WCsxiNuvE8QVDtzDYHgStKC+RmS6JjAvk7RrAo1osDULKGx+KRsSiCyFGspE72dRW4LCtDVMHa3sRvQ4o5e0iEp1ZPAV9EsAk3A4JNjVJe0masN4XAgreBXwgDcGEQb4hlgUO80IFnDb9GpYmcSNrmAlPAJhOmqUQ9kldLmggL9U1bDZMPI6AmOAH5NgXzNxkzEOW2QVEtAiKy2y3aa0CwMMgHMmtkhLL0QI9QI1RaIhqo4reoOhTqEuZb5xbTMLmN/Cdc1srkF37LyEA5C5zLT1QUPzTOg7F/rQRxg0ohfN6EY7+tF9UP80pCctg/dS+tKxxTOmN51pTntazZ8OtXs1LepGN9TSRpB0qWN1TlQXwdWrxlCrSY0tOm9UB7CuAisUbIOb6oJXlajxEGw605qioJGXgOlv8SeCXU/12CeglQF3oZHWHCDEn50orIOaZhzkmgpXyscNuoHX0UJkXG5NQlhP0NUj1ay9TFpHAbK6VRJ0x0VV4UVX0mGCdZcCApQYjAIOgEdfgE2t2qa1ITWrcBV8ewrHLKx7zKMwrUXbXH6L7UoCbm+N0YrPNnAsLcCDi6QuKrHWIQHFakIgcJhA5M1K6zi98QcnFTAsNzcuZx2MDMDo/OfZQe4YltOWS5DOfqwrAS//lKIA35SFLcU0Nw+jAZCcAEG/QB3QCOA9LV9wV+X5CPRTSGWw432ZWM0yiW/9YHOgA5292HG7zoUuhvHohT+agh929OccASiLX/cp3LXRhF2ssEgACBE0gb2721LseCY4I4BNFiAkJpFCG+F9aZfFfbTY8roOD+eWZnMQ+icUqRiby6B/4u5R6+bk1lz1Wr9ARoLxyAbkN8B67VXM9QP5dybCYgWctCL5FOiev9Bw83kRfq7Po4DnwIBwDUrvhM50pS1OTVIeqZRYEnCGcoPxm0psAxae/BQ4rWPogTqcYhNwncabkt5SSjwCCBQW7Uml7kZ8cbXkcxT+5pRwM4Bu/8jQcClAfU1we9mgFr80F/qjSOmXXwcnTGuXUad0Ajwhbj2gZUcWFldGLEdTDJMCZVVGCoflZTEzDWRXAhy4DsvAVQ7CLD1hEczCJoAwazPAbbGgfDaAgFRQMx0WPUVQJCt4BTwIBXAWgI8nAxhVGHWGawZYUoWxMkSAH1ywZ1LgZ4FwalFIBKoWa/7ig2CIUGI4hgRVhmYIUGiYhvy0hmyIT274hvT0hXJYh3Z4h3iYTXSYh3kWh3xITn74h+AUiILITYRYiNdUMG64h4h4LV7hhofYiIrwiGvWhBqFe53WB7tGAwUAcr62C6AgbEJgUqKwMRqRVsgmDDEFVknIGf8EkQLEhlMJ4QvXNgiUmAI6SEiYWGB+EG4zMEd/V3vmRknphgT+BlbWMnA5pIH/JT309i33pgBVMW8Ed1bIKFZG5ABltQA5ZHDOZwe3yFZtRWqRiAURNwITN05ZwzCItQCN8ncZh2PceDIdF36wxwMwNwL5OC2JR1gUsigpByn5oI05xIslsI8kAFnhxyw0FwjheALQFwvSF2F8QHTi0xJSYTovsTjutQ92gSgdYxmtdY/QgHhZUoQ6cHy8RQJ0k4LV4nUbIXZ2EXa6YBHucVsq+RTeVV69tYugJy4WYVxw53Z0dwd2tx+R8T624Bj2Y2/u+BJ/VwuBFxeDxxOFdxT/y3F1+FVbTsKMB/J15zJ5QlJKD1Bk64B5K/lS3TEYPJlgDplzwjWUQFeUdXB6z3UhL8R6JACMPFQWugAkDSSMCqh+KHB8uud7MRl8J2MdEMAsBpF/DmdgCuOWN6hpEWkkLVCOVWB9GZV9JGILfiRgZ5EKMvMS42cX5Yda6BcEHOZh6xcSKgaACXBi84cz9lcRInCbK6YuLfZinhBjiQeAzEeHBAgM5NiFaTCYMcEwwCQZELiXbeULFNgwbXGBJpCBQNCCSDYtSmYXDuJk+jhRJahBKLI03HkRv6WdL/gpX8YssylmzfZnzPdPudgTPqmZXACEXiWfQkCEXHCET5CE//NZibbmkxyBnHCQAFNIij5ghVuAhVGghYKgiAiaL98oibCCnxjqTBq6oWFYoR6KTh0aohkKoiQaTiN6oq2Soiq6KozYojAaozI6o0rwojQqoiZ6o9XEojqaGDzao4rwhYt4oUCKCPsEiTlapNlGkUBVoBaVpN6kCr8iimfAoFDyMieQisrWbwI6DbCYpcUmPTNjKNgGjtF1T/UJoAcIpWIACwCRKWw6BccIVV/JjdbYLPL2jIg1EdIojFn6VALpVbjhQzqBVsl1poNVnLGgcD86H4VzJRtxNP8gDGVJl37Fby+HqW2zkAZzcgDZlwPpG43JdQjJJMhBZgoyWckFl/9Bx6qZ9WByFxZxCgaH9EPmZzjSiHjA8R4rNQlbaRVp2WMwqUE4s3K0lapch1u4OCCzGaxrp06uinOcJZdEOatfUAwNoBTF83pigxkuYa1DkJP61ZbN8ngyKXlTISSckBrZAF7BagLe1QB/YxGUiQf7pGpw9wKN6i0uUVqzMRfZYUOzYV9eIK5ENJnlmpuJWQLCZx2BYRF68667V1MdxlM6Za8GeJloo6/g2gXSMA6z4Rgd1gsDK2epdS6uKZD8WAKySZuGYpu8V5j6134Mq40zRqXyZICKWoyZ2bFcICXF43qbFSEmewXa6YHcuWXv+azh2WMOYoLl6ZJbdwLqaQv/BoJlLNN/8XmohZlWaWqgByqHatoEXWqmTMqwTsqxcgihUCCheiCk4GqjShoJ+zq3jVC3drsIeJu3ibC3fHsIfvu3hRC4gmuLPlu40kG4iAsIcru4jvu4kHtpjRu5JapQREq58HW4LqC4mPtqCGqJmwW2yJcGv3IJwmcrcgWmDKEu1ZalTuZSJrClJxUtKgAas+JxZcp8OYhmOyi6S4gGMZEfMiERbTCngXokA1dwpRBebzVvWmUMxntSgOqnXWZDTne5oIecO1u0Z3sGLqEJlmIZp/AR3JBT7sEw6WBVC9MwB+AzUttnmnoCMvlONaJMdIdyMhO/T6a/9RcTeDUp/w05oUEZqwCksT5HwLLKBht7KZyQDG4jGJHhJmgzOBiZFmczObzTBDkpfwSCf9nAP9sVk76wwSqJrLuRCcLJtIw7wAi8vcWFwJY6BmIhABa5O8phktjQPntXQdITsUmwwYyHmyVAPCFMrMGKlsoKVmsnGVzSectnuDSQr5WmuUigEpDhORUGEc7jPDPkFSdEYKlGWQH2ZABKxP21sEkMmWHjZbUgL1P7xOKEnAY8gFR8BH2xR266G0JSFuuQw6IUmnEExkXQmjRrKGoqnGH7siYmf+dCYPrFC+zAVc3zZ4hcmRCVY3TcBm0BEHfcGrMpKaPkNBn0nF/sBEerCVdLLP8zCC1Nq0FSRp5JZmVJe2Qs2J0vyBTNZhG0bINlhpxfm8mUNrZMULa6m4NpO8WXxrZP4LaDMLmsib2dywbOHM2qwrnU7E51fM2Am83aPLjc3M1QDM4c+s3ibMnl/KHnjM7pzGrkvM57MM3u7C/w3APzHM9d8KPWbM/wvG3HjMwbxg/t6gLTqwUM+hThiYqvW2Ow62x1laUokCvh6TK5q4T+DAO/DMxWEH01maylwNFVEL0z5px2akW0fFUDJkjZwb8g7R5GRJ7UsBEHF84x4Grbq73t3ALPELwZpA3lq5PqsCYdcamUNarPw6l7WVgJDFd053IHyb8sxxSjYQwBHMf/GP0Cc1zVVOBWD6KUImATOAEhUgGULsQaW1DCldN4ugdbv5uJYSmz/eYA6XBreKEg4qbC5jzT0apz1ErAKYUF8XKrNOEi7/GRvuENXOF3vtpvS4zW32LGozbEl+euaXwukaVbpwEBsswR0CwHsCarCLzXsdrXV0AfGjI6FmY9/ZJKNw0Dx/ewbZwlCLtfbD26Y2d89WJeTtKsjAzHDtmFrnbVFV0F+2DFZaR9oLlxx2UWPFHQCrV+kyIZwMmyI6aPoLFOHlx2LLYbZdV0R7ITN9vLWJ2ZmBzeUhAufUxKbfKAAuIeVrseWXDKkRxmdg1l69NasBxl9l3bKFC1m4Ke/8kn2bws00/KhLyrixKFUMK8BMRM0TPdhaD7hAdeUMrsBMxM1Z+w2fSM4facaBq+4R7+4SBecx0e4ttM4qaSzyb+BSie4ve82izOBiv+4loQ4zKOBTRe4wbl4jh+Bje+42+m4z6uwRo+z/Uc5EjYzj1u5Ab5Ag9OkpsL5L8RCqc7A6ysQRM9xFe+AybliuiBpf32Y7LLkmEqbRcLVl9qKxRRi25gaRettoiQJqI8A3rjw8QgyDgA0v+ARw0z0svrjM9rMCySP9cAcPR4jX/6ldkB3SN+BZZW0w2eCLHQSyyzcuTgvr9lWYclDehAg6brM5NqD7XSA/s4b3g1C5Gl5v/n4qldzUM3YcQy2dSAxb+pugt2HgZtF6sGDMNQ7td/kVWzsZyI0zmU436nVBawhFtT4RS1sDZDcRVZoZW76cUSq9ZgqS5w7R4a5GW9Otl7+S22xSS+W9Ys7HagPZe7PtqdgCgGdmK41MPyglTSkD4T8lfF0BeLwpYWQdbQjt1hS66yncgy2UhWk2yb910l/auw6XltYGlS7OaHIEL/mkulXAl+IvGasJwGYl/xoT2Kp9ghUXWxnV0K24wqu7JrLbGN7H1aV6/21HDA/eSQjsrp9kUmWcrsMBHjcey18AALVERH1BM7su9PQQpHUkjRXXu+0awoBg26EK/No0HMGKz/kPyuUyHdC99wjj7gb24MwCM9piSDucQOhQH28dAWrw1J0vAnyLSB3Ym0fgZmS8tRJPi0sFxKXsYssQFmtbxlt6yd315b/JkGbF7g9vnojZjgSrDgZoBqTR7uSU5OE94EFa4G9ZxrRa7kZPD4mL8El7/5nv/5oB8DnR/6nH3upJ/jp2+kpp/6P876hqD5rg8EsB/7PjD7tN8CNrqGo3/7pHecP2D7L15U69T45H0HvWLl+13rPab8RbDlGuEbrQBWYN4Ry9aKz3/mrLi65kumd1BUDdXmDr8H0UcKCy5NdZ5TUYDnhNowid7nzltv6MinrZPnAUmn7MbzRyIuL22o/9kLAoA4kuUYCKmaBqZbBu0707V94zmQAowhEACBQ28xGCgKgIHgMVgoAYcjRCpwBBgHGUMxaDx04tnBaCo4RIvwqFwiLESPOMARFYFFDgZazSaVDdAMBAkoEQj2JI4xNjqaxIwhrKwgjEU+Zmpq8lg17AgiBiwIxDEtKAh8pio0CECkIgwkMAEUICCMLm7mIJr4CsnYIjCUKAQFixCS5C0RAGO+7ZbcFgc4lP0N3PF2eyMOxIiPk49TUpank4d7t7u7dBIICM6LBNbXAvwAIGCh0CeqBUEAkR7vbAAjAU3YKBOLMC0bQQDLAgfPEkXyMktEQhMLZCiAAMFAQSHIDv+iFANO3bpwMc6tYMmSXcqanATYKwUKACt5gvLVuiKOSL0lOFGctOmiowhaIgJUGVasxCIIMjaSKECAgR2nQqJKe7GATgIDIm6dSKp0LSRhNKJNgmlJTDS2dm2kIHAAVzF8TQ74JTDwk6sAeltc2VorgQADej/dBZBQrwgESgwkeEqnxIKpZYfZSwqBjmV9mX8tYiBj7AgGpROkUTM18t26M6KhgOkWh23avkWsaHC6XoJJTH4KMK6kwIJJuYSkoIUTwIMfAnYrVWBAVuYAiQ4YMKDgLDEXW0ZoJ6lMhoEnUcCLd6Gdu2ScPo8QAX/kdAGzv+325kI0/Z1jADe8Yff/n4ILMmiDgQ0+VRKEBwXYVlYBxJXLgQhO2KGHDFa3oW/gfXjQMzdUmMmJJbLYoosvwohigjHSWKONN+JIQoo58tijjz+ytSOQQxJZpJEyHpmkkksquSKTT0IZpZRTUlmllVdimaWWEzq5pZdfgnnbjGGSWaaVQpqZpppHormmm2/m2Cacc9LZom1dKoVnnXvyKeBucnYDaJ+DqmmboAVgmIKGdI2Z4zPLbZUJLUQg8UKlOXixyWklJADVVAxYpVZTDURRwGwkqAbBe+KI2hQNaiWgxAHjlWloo9RYt8KDOQgKYwqfyHMrQtcJISEJRdFQ1HmPJJCpCWDspYQCBxBg/8AfI2AlyhkOPABBQBA8c2pTzrpACiBA4NGqlrbyChOxvAprowrPvOttM0N4C8UZRhRWbBFHJAGKdzIg+kUYgGGhBRdeNINDIIMkFdIbmw1swhx6KBGReWa4AMt0AJQVEQPTeFnXSjKNE9c5uaA8Dk1ENtbPA8Sy4koYKRjggE4l/KAAKYiFEg4pcSTXyiv65PJDs8nNUsstuXDcC8kjVCNCF/qScIyO2EEUxADtGSvR1G5MR0sBGm9DZpcnt5ybu22L8/KQ8wDGRAsImFWAKjvpTU8Ks+gU7E5SGFFPPX0zJjSxRQlEkNUqTa2GMFoNcO0SMHB9VRDF+BCGRqcxBf9y2jidnZnGhr0JqLudcFikX4snYnjsoTyTgOCC19OT7MARMg+rg9eCVCOhq7GZ2FRhboJVymyaDGqQtHfcREfgfRrqbgKqMiVztQ5zKCwAYDMKVRSFLHkWpQK0UQ/UvYNjpFSBC7UQEGXRyDgx5tgBkEktUUGsSUQznDlVNKgFsrzNBRmVW0pqdvMxZZykM2pTC6Dchg4d9OpFRfmZLVyBAFqVj2R7mQfsQGYcw8WFVglwxRXCkBvpyME68ULPdjbinfocYQBEaEB4SFWCZS3BAQ4ICEjCUxAexscE89mIPErwQGecxT9hYhcOCESJXXWPUD/CIoOGUKs/zfAsiUr/TgBE9JYwatFFIWoQib74BnWhRE9pnOOaMkjHO+KRUXncIx95Ycc+ArKPfwwkIe84yEIiklCHTCQj67TIRkLSTXKMJCUraclLYjKTfSQA3DrpyU+CMpSiHCUpSQlHTcZoYKVcJSs/eYRWwjKWM0EjKj30yBvd0ka5rCVtdkkjX6aSlryEEDBhVMwXHXOYNkmmnYT5I2YqEyXQLNE0P1TNaLbjmh3S5oS4ic1NTJJJ4VzSOL9pznOiM53qXCc72+nOdzKpAFYRlxR+B6Xm3dNT8PzNACDwADtQBVyRYlKzIqckaJVmn3fpAwDWQJVTFulhVtKYQteyEKqALUrEe1LV/yrKlouiqgfWgtJGmfQRj9rFK1B5gTd9U1IlARClbCkNZiRTEAVaLkkvPVJMZboW+NDqhuELD62YtER8Nmke+PEpU5vq1KdCNapSnSpVq2rVq2I1q1rdKle76tWvgjWsYh3rMJ/xqBmQawaTGoNZCRCFtTqkqGSFJCVyqownngBdqoEoPFYQhr3Cw6BzDSQP2ieZBiAhY9PRyAIScL8FHGCviCKCav5qhMY6ESftA2wC+EUUQXTKroPlIw8GEoeZNSAVn8gHFhTQD9g05hjEcoAlBhJZvGGIe8DBiWnrk4XGjOIT87gFF0cLSF0poTDXwEk+COCFSUAnCIJDwQMaYLUZ03oHXSNArm8Z44CQKEGpCECqcUkrgFQA1G7iMAp1VFGdo6BLcAwohU5Q8JEYnCoF6D0EsZwwCbOkQGd8LW8aecCETwyGABcL3nX+CV/DCE4feQFZYx7g3OYZeG/BgoOFceE+75qRwHTkgWsct9y9Oe0HQsQJV1QRYYSN4L2NyS+LJ0Gt6/gAZ5mpBwr4J+IfAznIQh4ykYts5CMjOclKXjKTm+zkJ0M5ylKeMpWrbOUr3zEEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Increased relative risk of stroke with lisinopril. Graph, with natural logarithmic scale, showing the relative risk of stroke in all studied patients (total) and prespecified subgroups given either lisinopril or chlorthalidone in the ALLHAT study. Compared with chlorthalidone, lisinopril increased the risk of stroke in total and in some specific subgroups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from the ALLHAT investigators, JAMA 2002; 288:2981.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13524=[""].join("\n");
var outline_f13_13_13524=null;
var title_f13_13_13525="Sitagliptin: Patient drug information";
var content_f13_13_13525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sitagliptin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=see_link\">",
"     see \"Sitagliptin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3415811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Januvia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9748132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Januvia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10078319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028325\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702930",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sitagliptin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you abuse beer, wine, or mixed drinks, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697221",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have gallbladder disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697318",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have pancreatitis, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698350",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sore throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose stuffiness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698316",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Runny nose.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028328\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028334\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11868 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13525=[""].join("\n");
var outline_f13_13_13525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3415811\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9748132\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10078319\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028325\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028324\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028329\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028330\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028332\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028327\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028328\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028333\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028334\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/31/5622?source=related_link\">",
"      Sitagliptin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_13_13526="Omacetaxine: Drug information";
var content_f13_13_13526=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Omacetaxine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20660?source=see_link\">",
"    see \"Omacetaxine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F15592818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synribo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F15512860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Cephalotaxine;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Protein Synthesis Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F15515971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Chronic myelogenous leukemia (CML), chronic or accelerated phase:",
"     </b>",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Induction:",
"     </i>",
"     1.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 14 consecutive days of a 28-day treatment cycle; continue until hematologic response is achieved",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Maintenance:",
"     </i>",
"     1.25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily for 7 consecutive days of a 28-day treatment cycle; continue until no longer achieving clinical treatment benefit",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Dosage adjustment in obesity:",
"     </b>",
"     <i>",
"      ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:",
"     </i>",
"     Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F15515972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15515974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied). Based on the minimal amount of unchanged drug excreted in the urine, dosage adjustment is not likely necessary (Nemunaitis, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15515975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in the manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F15515973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Hematologic toxicity:",
"     </b>",
"     May delay treatment cycles and/or reduce the number of treatment days during a cycle for hematologic toxicities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Neutropenia grade 4 (ANC &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) or thrombocytopenia &ge; grade 3 (platelets &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     ) during a cycle: Delay the start of the next cycle until ANC &ge;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and platelets &ge;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     <b>",
"      AND",
"     </b>",
"     reduce the number of treatment days by 2 days (eg, reduce from 14 days to 12 days or reduce from 7 days to 5 days)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     <b>",
"      Nonhematologic toxicity:",
"     </b>",
"     Manage symptomatically; interrupt and/or delay treatment until toxicity resolves.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F15593679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as mepesuccinate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synribo&trade;: 3.5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F15515929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F15515976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer subcutaneously.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F15512862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of chronic or accelerated phase chronic myelogenous leukemia (CML) in patients resistant and/or intolerant to &ge;2 tyrosine kinase inhibitors",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F15515928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medical Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F15515925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Peripheral edema (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (26% to 31%), fever (24% to 29%), headache (13% to 19%), chills (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Alopecia (15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Uric acid increased (grades 3/4: 56% to 57%), hyperglycemia (grades 3/4: 10% to 15%; hyperosmolar nonketotic hyperglycemia: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Diarrhea (35% to 42%), nausea (27% to 32%), constipation (15%), vomiting (12% to 15%), abdominal pain (13% to 14%), anorexia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Thrombocytopenia (grades 3/4: 49% to 88%), neutropenia (grades 3/4: 18% to 81%), anemia (grades 3/4: 36% to 80%), leukocytes decreased (grades 3/4: 61% to 72%), neutropenic fever (10% to 20%; grades 3/4: 10% to 16%), lymphopenia (17%; grades 3/4: 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (22% to 34%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Weakness (23% to 24%), arthralgia (19%), limb pain (11% to 13%), back pain (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Creatinine increased (grades 3/4: 9% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Cough (&le;16%), epistaxis (11% to 15%), dyspnea (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (46% to 56%; grades 3/4: 11% to 20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Acute coronary syndrome, angina pectoris, arrhythmia, bradycardia, cerebral hemorrhage, chest pain, edema, hyper-/hypotension, palpitations, tachycardia, ventricular extrasystoles",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Insomnia (10%), anxiety, agitation, confusion, depression, dizziness, dysphonia, hyperthermia, hypoesthesia, lethargy, malaise, mental status change, pain, seizures",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Bruising, burning sensation, dry skin, erythema, hyperhidrosis, hyperpigmentation, petechiae, pruritus, purpura, rash, skin exfoliation, skin lesions, skin ulceration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Glucose decreased (grades 3/4: 6% to 8%), dehydration, diabetes mellitus, gout, hot flashes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal distension, abnormal taste, anal fissure, aphthous stomatitis, appetite decreased, dyspepsia, dysphagia, gastritis, gastroesophageal reflux disease, GI bleeding, gingival bleeding, gingival pain, gingivitis, hemorrhoids, melena, mouth ulceration, mouth hemorrhage, mucosal inflammation, oral pain, stomatitis, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Dysuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hematologic: Bone marrow failure (10%; grades 3/4: 10%), hematoma",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: Bilirubin increased (grades 3/4: 6% to 9%), ALT increased (grades 3/4: 2% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Bone pain, muscle spasms, muscle weakness, musculoskeletal chest pain, musculoskeletal discomfort, musculoskeletal pain myalgia, paresthesia, sciatica, stiffness, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision, cataract, conjunctival hemorrhage, conjunctivitis, diplopia, dry eyes, eye pain, eyelid edema, lacrimation increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Otic: Ear hemorrhage, ear pain, tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hemoptysis, nasal congestion, pharyngolaryngeal pain, rales, rhinorrhea, sinus congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like syndrome, hypersensitivity reactions, night sweats, transfusion reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F15515933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15515934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:  Grade 3/4 neutropenia, thrombocytopenia and anemia commonly occur;  generally reversible, although may require treatment delay and/or a reduction in the number of treatment days with future cycles. Myelosuppression may rarely be fatal. Monitor blood counts (in induction and maintenance cycles). Neutropenia may increase the risk for infection. Thrombocytopenia may increase the risk of bleeding; cerebrovascular hemorrhages have been reported (some fatal); gastrointestinal hemorrhages have occurred. Due to the increased risk of bleeding, avoid the use of anticoagulants, aspirin, and NSAIDs when the platelet count is &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glucose intolerance: Omacetaxine may induce glucose intolerance.  Hyperglycemia has been observed; hyperosmolar nonketotic hyperglycemia has been reported (case report). Monitor blood glucose frequently, especially in patients with diabetes or with risk factors for diabetes. Avoid use in patients with poorly controlled diabetes; may initiate after glycemic control has been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticoagulants:  Due to the increased risk of bleeding, avoid the use of anticoagulants, aspirin, and NSAIDs when the platelet count is &lt;50,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Patients &ge;65 years of age are more likely to experience hematologic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (meets NIOSH, 2012 criteria)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F15517163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F15517161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of aspirin with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Antineoplastic Agents may decrease the absorption of Cardiac Glycosides. This may only affect digoxin tablets.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Digitoxin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased. Management: Avoid concurrent use of nonsteroidal antiinflammatory drugs (NSAIDs) with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Antineoplastic Agents may enhance the anticoagulant effect of Vitamin K Antagonists. Antineoplastic Agents may diminish the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F15516380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F15515930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies at doses less than the equivalent human dose (based on BSA). Based on the mechanism of action, omacetaxine may cause fetal harm if administered during pregnancy. Women of reproductive potential should avoid pregnancy during therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F15515931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15515932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if omacetaxine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the decision to discontinue omacetaxine or to discontinue breast-feeding should take into account the importance of treatment to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Synribo Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     3.5 mg (1): $1002.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F15515979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential (weekly during induction and initial maintenance cycles, then every 2 weeks or as clinically indicated after initial maintenance cycles); blood glucose (frequently); signs/symptoms of infection; signs of bleeding",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F15515958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Omacetaxine is a reversible protein synthesis inhibitor which binds to the A-site cleft of the ribosomal subunit to interfere with chain elongation and inhibit protein synthesis. It acts independently of BCR-ABL1 kinase-binding activity, and has demonstrated activity against tyrosine kinase inhibitor-resistant BCR-ABL mutations.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F15515960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic phase CML: Mean time to major cytogenetic response: 3.5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Accelerated phase CML: Mean time to response: 2.3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Chronic phase CML: Median duration of major cytogenetic response: 12.5 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Accelerated phase CML: Median duration of complete hematologic response: 4.7 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: SubQ: Rapid (Nemunaitis, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 141 &plusmn; 93 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: &le;50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hydrolyzed by plasma esterases to 4&rsquo;-DMHHT; minimal hepatic metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: SubQ: ~30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&lt;15%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cortes J, Lipton JH, Rea D, et al, &ldquo;Phase 2 Study of Subcutaneous Omacetaxine Mepesuccinate After TKI Failure in Patients With Chronic-Phase CML With T315I Mutation,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2012, 120(13):2573-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/22896000/pubmed\" id=\"22896000\" target=\"_blank\">",
"        22896000",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cortes, JE, Nicolini FE, Wetzler M, et al, &ldquo;Subcutaneous Omacetaxine in Chronic or Accelerated Chronic Myeloid Leukemia Resistant to Two or More Tyrosine-Kinase Inhibitors Including Imatinib,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 2011, 118(21):3761 [abstract 3761 from 2011 ASH Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coude MM, Luycx O, Cariou ME, et al, &ldquo;Undetectable Molecular Residual Disease After Omacetaxine and Nilotinib Combination Therapy in an Imatinib-Resistant Chronic Myeloid Leukaemia Patient Harbouring the BCR-ABL1 T315I Gatekeeper Mutation,&rdquo;",
"      <i>",
"       Br J Haematol",
"      </i>",
"      , 2012, 157(3):407-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/22225474/pubmed\" id=\"22225474\" target=\"_blank\">",
"        22225474",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klag T, H&auml;rtel N, Erben P, et al, &ldquo;Omacetaxine Mepesuccinate Prevents Cytokine-Dependent Resistance to Nilotinib",
"      <i>",
"       in vitro",
"      </i>",
"      : Potential Role of the Common &Beta;-Subunit C of Cytokine Receptors,&rdquo;",
"      <i>",
"       Leukemia",
"      </i>",
"      , 2012, 26(6):1321-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/22289991/pubmed\" id=\"22289991\" target=\"_blank\">",
"        22289991",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nemunaitis J, Mita A, Stephenson J, et al, &ldquo;Pharmacokinetic Study of Omacetaxine Mepesuccinate Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors,&rdquo;",
"      <i>",
"       Cancer Chemother Pharmacol",
"      </i>",
"      , 2013, 71(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/23053254/pubmed\" id=\"23053254\" target=\"_blank\">",
"        23053254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nicolini FE, Lipton JH, Kantarjian H, et al, &ldquo;Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) Resistant/Intolerant to Two or Three Approved Tyrosine-Kinase Inhibitors (TKIs),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(152):6513 [abstract 6513 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Quint&aacute;s-Cardama A, Kantarjian H, and Cortes J, &ldquo;Homoharringtonine, Omacetaxine Mepesuccinate, and Chronic Myeloid Leukemia Circa 2009,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2009, 115(23):5382-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?13/13/13526/abstract-text/19739234/pubmed\" id=\"19739234\" target=\"_blank\">",
"        19739234",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wetzler M, Kantarjian H, Nicolini FE, et al, &ldquo;Pooled Safety Analysis of Omacetaxine Mepesuccinate in Patients With Chronic Myeloid Leukemia (CML) Resistant to Tyrosine-Kinase Inhibitors (TKIs),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(152):6604 [abstract 6604 from 2012 ASCO Annual Meeting].",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87038 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-27.109.116.13-BBD231414A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13526=[""].join("\n");
var outline_f13_13_13526=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15592818\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512860\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515971\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515972\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515974\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515975\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515973\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15593679\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515929\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515976\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15512862\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515928\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515925\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515933\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515934\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15517163\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15517161\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15516380\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515930\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515931\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515932\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570459\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515979\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515958\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15515960\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87038\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/87038|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?20/11/20660?source=related_link\">",
"      Omacetaxine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_13_13527="Overview of the causes and treatment of hyperphosphatemia";
var content_f13_13_13527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the causes and treatment of hyperphosphatemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Jason R Stubbs, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Alan S L Yu, MB, BChir",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Stanley Goldfarb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13527/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/13/13527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phosphate is an inorganic molecule consisting of a central phosphorus atom and four oxygen atoms. In the steady state, the serum phosphate concentration is primarily determined by the ability of the kidneys to excrete dietary phosphate. The diagnostic approach to hyperphosphatemia involves elucidating why phosphate entry into the extracellular fluid exceeds the degree to which it can be excreted in order to maintain normal plasma levels.",
"   </p>",
"   <p>",
"    A broad overview of the causes and treatment of hyperphosphatemia is presented in this topic. Detailed discussions of renal osteodystrophy and the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9791355\">",
"    <span class=\"h1\">",
"     OVERVIEW OF THE CAUSES OF HYPERPHOSPHATEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal excretion is so efficient in normal subjects that balance can be maintained with only a minimal rise in serum phosphate concentration even if phosphate intake is increased to as much as 4000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (130",
"    <span class=\"nowrap\">",
"     mmol/day).",
"    </span>",
"    Phosphate intake above 4000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (130",
"    <span class=\"nowrap\">",
"     mmol/day)",
"    </span>",
"    causes only small elevations in serum phosphate concentrations as long as the intake is distributed over the course of the day. If, however, an acute phosphate load is given over several hours, transient hyperphosphatemia will ensue.",
"   </p>",
"   <p>",
"    The diagnostic approach to hyperphosphatemia involves elucidating why phosphate entry into the extracellular fluid exceeds the degree to which it can be excreted or why the renal threshold for phosphate excretion is increased above normal. There are three general circumstances in which this occurs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Massive acute phosphate load",
"     </li>",
"     <li>",
"      Acute or chronic kidney disease",
"     </li>",
"     <li>",
"      A primary increase in tubular phosphate reabsorption",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Massive acute phosphate load",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phosphate load sufficient to overwhelm renal capacity for excretion can be derived from either endogenous or exogenous sources. Since phosphate is the major intracellular anion, any cause of marked tissue breakdown can lead to release of intracellular phosphate into the extracellular fluid. The ensuing hyperphosphatemia may then induce potentially symptomatic hypocalcemia due to calcium-phosphate precipitation in the tissues. Examples of marked tissue breakdown include tumor lysis syndrome, muscle necrosis (rhabdomyolysis), and, rarely, marked hemolysis or transfusion of stored blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Tumor lysis syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor lysis syndrome is most often caused by cytotoxic therapy in patients with a large burden of a tumor characterized by rapid cell turnover, such as lymphomas (particularly Burkitt's lymphoma and non-Hodgkin lymphoma) and certain leukemias [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition to release of phosphate, this syndrome is also associated with the release of potassium, purines (which can be metabolized to uric acid), and cell proteins (which can be metabolized to urea). Thus, hyperkalemia, hyperuricemia (which may lead to acute renal failure), and azotemia are other common metabolic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=see_link\">",
"     \"Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Rhabdomyolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar considerations apply to rhabdomyolysis except that myoglobin is also released from the damaged cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The severity of the hyperphosphatemia and hypocalcemia may be increased if heme pigment-induced acute kidney injury (AKI) ensues. In these patients, resolution of the renal injury can lead to hypercalcemia as the serum phosphate concentration falls and the tissue calcium-phosphate deposits are mobilized [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=see_link&amp;anchor=H25399006#H25399006\">",
"     \"Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Lactic and ketoacidosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other causes of mobilization of intracellular phosphate into the extracellular fluid are lactic acidosis and diabetic ketoacidosis (or severe hyperglycemia alone) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In addition to promoting a shift of phosphate out of cells, metabolic acidosis can diminish glycolysis and therefore cellular phosphate utilization. In the case of lactic acidosis, concurrent tissue hypoxia and cell death is likely to further contribute to a decreased consumption and increased release of phosphate from cells. Patients with diabetic ketoacidosis are usually phosphate depleted, resulting from both transcellular shifts of phosphate into the extracellular fluid due to chronic insulin deficiency and phosphaturia associated with the osmotic diuresis induced by hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/8\">",
"     8",
"    </a>",
"    ]. The phosphate deficiency in these patients will typically be unmasked (leading to hypophosphatemia) by the administration of insulin. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults\", section on 'Serum phosphate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Exogenous phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia from exogenous sources is most commonly induced by the ingestion of large amounts of phosphate-containing laxatives [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/9-12\">",
"     9-12",
"    </a>",
"    ]. Fleet's Phospho-Soda, for example, contains 4.25 mmol of inorganic phosphate per mL. As a result, 20 mL taken over three to six hours can cause severe, even fatal, hyperphosphatemia and hypocalcemia.",
"   </p>",
"   <p>",
"    In addition to absorption of the excess phosphate, volume contraction (due to diarrhea) and mild renal insufficiency (due to decreased renal perfusion) may contribute to hyperphosphatemia in this setting. A review of the literature suggests that patients with underlying chronic kidney disease (CKD) are at particularly high risk for hyperphosphatemia due to phosphate-containing laxatives [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Acute phosphate nephropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of reports describing acute or subacute kidney injury (called acute phosphate nephropathy or phosphate nephropathy) occurring after the ingestion of sodium-phosphate laxatives (solution or tablets) as bowel preparation for colonoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. This is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"     \"Acute phosphate nephropathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Acute or chronic kidney disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The filtered load of phosphate is approximately 4 to 8",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    (130 to 194",
"    <span class=\"nowrap\">",
"     mmol/day).",
"    </span>",
"    If, for example, the glomerular filtration rate (GFR) is 180",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and the phosphate concentration is 4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.3",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    then the filtered load will be 7.2",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    Only 5 to 20 percent of the filtered phosphate is normally excreted, with most being reabsorbed in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The normal physiologic regulation of renal phosphate excretion is elsewhere in detail; briefly, the following factors are involved (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of hypophosphatemia\", section on 'Increased urinary excretion'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum phosphate concentration &ndash; Hyperphosphatemia can directly diminish proximal tubular phosphate reabsorption via suppression of sodium-phosphate cotransporters in the luminal membrane that allow reabsorption of filtered phosphate.",
"     </li>",
"     <li>",
"      Parathyroid hormone &ndash; Parathyroid hormone (PTH) increases phosphate excretion by diminishing activity of sodium-phosphate cotransporters.",
"     </li>",
"     <li>",
"      Phosphatonins &ndash; Phosphatonins such as fibroblast growth factor 23 (FGF23) and secreted frizzled related protein-4 (sFRP-4) decrease phosphate reabsorption by suppressing the luminal expression of sodium-phosphate cotransporters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acute or chronic reduction in GFR will initially diminish phosphate filtration and excretion. Nevertheless, phosphate balance can initially be maintained in such patients by decreasing proximal phosphate reabsorption under the influence of increased secretion of PTH and FGF23. Once the GFR falls below 20 to 25",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    however, phosphate reabsorption is thought to be maximally suppressed, and urinary excretion may no longer keep pace with phosphate intake. At this point, hyperphosphatemia must occur to increase the filtered load and reestablish phosphate balance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased tubular reabsorption of phosphate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to a reduction in GFR, phosphate excretion can also be diminished by an increase in proximal phosphate reabsorption. This usually occurs in patients with otherwise normal renal function who have one of the following conditions:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Hypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Either deficient PTH secretion or renal resistance to PTH (pseudohypoparathyroidism) results in increased phosphate reabsorption and leads to hyperphosphatemia. These patients also have hypocalcemia due to reduced bone resorption and urinary calcium losses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=see_link\">",
"     \"Etiology of hypocalcemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment with calcium and vitamin D (or calcitriol [1,25-dihydroxyvitamin D, the most active metabolite of vitamin D]) lowers the serum phosphate concentration, although not always to the normal range. How this occurs is not clear, although two potential mechanisms include the following: calcium and vitamin D therapy increase the serum calcium concentration, which may directly diminish phosphate transport in the proximal tubule; calcitriol stimulates FGF23 production by bone, which could lead to a suppression of phosphate reabsorption by the proximal tubule.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Acromegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia occurs in some patients with acromegaly. It is presumably due to direct stimulation of phosphate reabsorption by growth hormones or insulin-like growth factor I [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=see_link\">",
"     \"Causes and clinical manifestations of acromegaly\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates, primarily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    , can cause mild hyperphosphatemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. This effect is mediated in part by direct stimulation of renal phosphate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Vitamin D toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperphosphatemia may be associated with vitamin D toxicity. Vitamin D increases both phosphate and calcium absorption, and the rise in serum calcium concentration diminishes urinary phosphate excretion, both by inhibiting PTH secretion and, in many cases, by impairing renal function (in part due to direct renal vasoconstriction).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Familial tumoral calcinosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial tumoral calcinosis is a rare autosomal recessive disorder characterized by hyperphosphatemia due to an increase in proximal tubular phosphate transport, often in association with increased serum calcitriol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/22\">",
"     22",
"    </a>",
"    ]. The underlying defect that was first described was a mutation in the GALNT3 gene, which encodes a glycosyltransferase that is thought to prevent the degradation of FGF23 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Gene mutations in FGF23 and Klotho (the FGF23 co-receptor) have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/25-28\">",
"     25-28",
"    </a>",
"    ]. It is postulated that inactivating mutations in either the GALNT3 or FGF23 genes could lead to deficiency of circulating intact FGF23, which is a promoter of renal phosphate excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, FGF23 requires Klotho to bind to its receptor; therefore, a deficiency in Klotho could lead to a state of FGF23 end-organ resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. FGF23 and Klotho are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=see_link&amp;anchor=H8#H8\">",
"     \"Pathogenesis of renal osteodystrophy\", section on 'Fibroblast growth factor 23'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Familial tumoral calcinosis appear to be the mirror image of X-linked and autosomal dominant hypophosphatemic rickets in which increased activity of FGF23 causes a primary increase in renal phosphate excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link\">",
"     \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum calcium and PTH concentrations are typically within the normal range in patients with familial tumoral calcinosis. The tendency of phosphate to complex with calcium and cause hypocalcemia appears to be counterbalanced by increased production of 1,25-dihyroxyvitamin D and perhaps hyperphosphatemia-induced stimulation of calcium reabsorption in the distal nephron. The combination of hyperphosphatemia and normocalcemia results in a high calcium-phosphate product and calcium-phosphate deposition in the skin and subcutaneous tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lowering the serum phosphate concentration by dietary restriction and phosphate binders, which impair intestinal phosphate absorption, often results in resolution of these deposits [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/22,32\">",
"     22,32",
"    </a>",
"    ]. If this is ineffective, increasing urinary phosphate excretion by the chronic administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pseudohyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spurious hyperphosphatemia due to interference with analytical methods may occur in patients with hyperglobulinemia, hyperlipidemia, hemolysis, and hyperbilirubinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Among these conditions, the most common is hyperglobulinemia due to multiple myeloma, Waldenstr&ouml;m's macroglobulinemia, or monoclonal gammopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Extreme pseudohyperphosphatemia due to therapy with high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     liposomal amphotericin B",
"    </a>",
"    has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/38\">",
"     38",
"    </a>",
"    ], as has spurious hyperphosphatemia due to sample contamination with recombinant tissue plasminogen activator or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Phosphate can be determined accurately by use of alternative analysis methods [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13527/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT OF HYPERPHOSPHATEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to therapy differs in acute and chronic hyperphosphatemia. Acute severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. The hyperphosphatemia usually resolves within 6 to 12 hours if renal function is intact. Phosphate excretion can be increased by saline infusion, although this can further reduce the serum calcium concentration by dilution. Hemodialysis is often indicated in patients with symptomatic hypocalcemia, particularly if renal function is impaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Chronic hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hyperphosphatemia requiring therapy occurs in patients with chronic renal failure and familial tumoral calcinosis. Treatment consists of diminishing intestinal phosphate absorption by a low-phosphate diet and phosphate binders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperphosphatemia results when phosphate entry into the extracellular fluid exceeds the rate at which it can be excreted. This occurs when there is a large phosphate load over a short period of time (which may be from endogenous or exogenous sources), in chronic renal failure, and as a result of a primary increase in proximal phosphate reabsorption. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased extracellular phosphate from endogenous sources occurs in tumor lysis syndrome, muscle necrosis (rhabdomyolysis), and, rarely, marked hemolysis or transfusion of stored blood. Lactic acidosis and diabetic ketoacidosis (or severe hyperglycemia alone) may also cause increased mobilization of intracellular phosphate into the extracellular fluid. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Massive acute phosphate load'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An acute exogenous phosphate load may result from the ingestion of a large amount of a phosphate-containing laxative. Volume contraction (due to diarrhea) and mild renal insufficiency (due to decreased renal perfusion) may contribute to hyperphosphatemia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Exogenous phosphate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal failure is a common cause of diminished phosphate excretion. Urinary excretion may not keep pace with phosphate intake when the glomerular filtration rate (GFR) falls below 20 to 25",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Acute or chronic kidney disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increased proximal phosphate reabsorption occurs in patients with hypoparathyroidism or acromegaly, during treatment with bisphosphonates or vitamin D, and due to a heritable condition called familial tumoral calcinosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Increased tubular reabsorption of phosphate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pseudohyperphosphatemia may be caused by interference with analytical methods in patients with hyperglobulinemia, hyperlipidemia, hemolysis, and hyperbilirubinemia and has been reported with high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"       liposomal amphotericin B",
"      </a>",
"      , recombinant tissue plasminogen activator, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pseudohyperphosphatemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Severe hyperphosphatemia with symptomatic hypocalcemia can be life-threatening. Phosphate excretion can be increased by saline infusion if renal function is intact. Hemodialysis is often indicated in patients with symptomatic hypocalcemia, particularly if renal function is impaired. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment of hyperphosphatemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic hyperphosphatemia occurs in patients with chronic renal failure and familial tumoral calcinosis. Treatment consists of diminishing intestinal phosphate absorption by a low-phosphate diet and phosphate binders. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Chronic hyperphosphatemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H473792928\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and UpToDate would like to thank Dr. Zalman Agus, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/1\">",
"      Tsokos GC, Balow JE, Spiegel RJ, Magrath IT. Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) 1981; 60:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/2\">",
"      Hande KR, Garrow GC. Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma. Am J Med 1993; 94:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/3\">",
"      Arrambide K, Toto RD. Tumor lysis syndrome. Semin Nephrol 1993; 13:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/4\">",
"      Grossman RA, Hamilton RW, Morse BM, et al. Nontraumatic rhabdomyolysis and acute renal failure. N Engl J Med 1974; 291:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/5\">",
"      Llach F, Felsenfeld AJ, Haussler MR. The pathophysiology of altered calcium metabolism in rhabdomyolysis-induced acute renal failure. Interactions of parathyroid hormone, 25-hydroxycholecalciferol, and 1,25-dihydroxycholecalciferol. N Engl J Med 1981; 305:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/6\">",
"      O'Connor LR, Klein KL, Bethune JE. Hyperphosphatemia in lactic acidosis. N Engl J Med 1977; 297:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/7\">",
"      Sternbach GL, Varon J. Severe hyperphosphatemia associated with hemorrhagic shock. Am J Emerg Med 1992; 10:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/8\">",
"      Kebler R, McDonald FD, Cadnapaphornchai P. Dynamic changes in serum phosphorus levels in diabetic ketoacidosis. Am J Med 1985; 79:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/9\">",
"      Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/10\">",
"      Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda in a patient with colonic ileus. Am J Gastroenterol 1993; 88:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/11\">",
"      Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/12\">",
"      Curran MP, Plosker GL. Oral sodium phosphate solution: a review of its use as a colorectal cleanser. Drugs 2004; 64:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/13\">",
"      Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003; 349:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/14\">",
"      Markowitz GS, Nasr SH, Klein P, et al. Renal failure due to acute nephrocalcinosis following oral sodium phosphate bowel cleansing. Hum Pathol 2004; 35:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/15\">",
"      Markowitz GS, Stokes MB, Radhakrishnan J, D'Agati VD. Acute phosphate nephropathy following oral sodium phosphate bowel purgative: an underrecognized cause of chronic renal failure. J Am Soc Nephrol 2005; 16:3389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/16\">",
"      Gonlusen G, Akgun H, Ertan A, et al. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch Pathol Lab Med 2006; 130:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/17\">",
"      Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/18\">",
"      Murer H, L&ouml;tscher M, Kaissling B, et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int 1996; 49:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/19\">",
"      Quigley R, Baum M. Effects of growth hormone and insulin-like growth factor I on rabbit proximal convoluted tubule transport. J Clin Invest 1991; 88:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/20\">",
"      Walton RJ, Russell RG, Smith R. Changes in the renal and extrarenal handling of phosphate induced by disodium etidronate (EHDP) in man. Clin Sci Mol Med 1975; 49:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/21\">",
"      Challa A, Noorwali AA, Bevington A, Russell RG. Cellular phosphate metabolism in patients receiving bisphosphonate therapy. Bone 1986; 7:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/22\">",
"      Mitnick PD, Goldfarb S, Slatopolsky E, et al. Calcium and phosphate metabolism in tumoral calcinosis. Ann Intern Med 1980; 92:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/23\">",
"      Topaz O, Shurman DL, Bergman R, et al. Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 2004; 36:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/24\">",
"      Frishberg Y, Ito N, Rinat C, et al. Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 2007; 22:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/25\">",
"      Chefetz I, Heller R, Galli-Tsinopoulou A, et al. A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification. Hum Genet 2005; 118:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/26\">",
"      Araya K, Fukumoto S, Backenroth R, et al. A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis. J Clin Endocrinol Metab 2005; 90:5523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/27\">",
"      Ichikawa S, Imel EA, Kreiter ML, et al. A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 2007; 117:2684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/28\">",
"      Yancovitch A, Hershkovitz D, Indelman M, et al. Novel mutations in GALNT3 causing hyperphosphatemic familial tumoral calcinosis. J Bone Miner Metab 2011; 29:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/29\">",
"      Kurosu H, Ogawa Y, Miyoshi M, et al. Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem 2006; 281:6120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/30\">",
"      Urakawa I, Yamazaki Y, Shimada T, et al. Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006; 444:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/31\">",
"      Slavin RE, Wen J, Kumar D, Evans EB. Familial tumoral calcinosis. A clinical, histopathologic, and ultrastructural study with an analysis of its calcifying process and pathogenesis. Am J Surg Pathol 1993; 17:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/32\">",
"      Mozaffarian G, Lafferty FW, Pearson OH. Treatment of tumoral calcinosis with phosphorus deprivation. Ann Intern Med 1972; 77:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/33\">",
"      Yamaguchi T, Sugimoto T, Imai Y, et al. Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide. Bone 1995; 16:247S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/34\">",
"      Larner AJ. Pseudohyperphosphatemia. Clin Biochem 1995; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/35\">",
"      Adler SG, Laidlaw SA, Lubran MM, Kopple JD. Hyperglobulinemia may spuriously elevate measured serum inorganic phosphate levels. Am J Kidney Dis 1988; 11:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/36\">",
"      Leehey DJ, Daugirdas JT, Ing TS, Reid RW. Spurious hyperphosphatemia due to hyperlipidemia. Arch Intern Med 1985; 145:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/37\">",
"      Randall AG, Garcia-Webb P, Beilby JP. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem 1990; 27 ( Pt 4):345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/38\">",
"      Lane JW, Rehak NN, Hortin GL, et al. Pseudohyperphosphatemia associated with high-dose liposomal amphotericin B therapy. Clin Chim Acta 2008; 387:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/39\">",
"      Schiller B, Virk B, Blair M, et al. Spurious hyperphosphatemia in patients on hemodialysis with catheters. Am J Kidney Dis 2008; 52:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13527/abstract/40\">",
"      Ball CL, Tobler K, Ross BC, et al. Spurious hyperphosphatemia due to sample contamination with heparinized saline from an indwelling catheter. Clin Chem Lab Med 2004; 42:107.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 828 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13527=[""].join("\n");
var outline_f13_13_13527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9791355\">",
"      OVERVIEW OF THE CAUSES OF HYPERPHOSPHATEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Massive acute phosphate load",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Tumor lysis syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Rhabdomyolysis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Lactic and ketoacidosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Exogenous phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Acute or chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased tubular reabsorption of phosphate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Acromegaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Vitamin D toxicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Familial tumoral calcinosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pseudohyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT OF HYPERPHOSPHATEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Chronic hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H473792928\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30776?source=related_link\">",
"      Causes and clinical manifestations of acromegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/25/15767?source=related_link\">",
"      Causes of hypophosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4986?source=related_link\">",
"      Clinical features and diagnosis of diabetic ketoacidosis and hyperosmolar hyperglycemic state in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24984?source=related_link\">",
"      Etiology of hypocalcemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21847?source=related_link\">",
"      Prevention and treatment of heme pigment-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19481?source=related_link\">",
"      Tumor lysis syndrome: Definition, pathogenesis, clinical manifestations, etiology and risk factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_13_13528="Clinical presentation, evaluation, and treatment of renal atheroemboli";
var content_f13_13_13528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical presentation, evaluation, and treatment of renal atheroemboli",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13528/contributors\">",
"     Francesco Scolari, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13528/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13528/contributors\">",
"     Gary C Curhan, MD, ScD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13528/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/13/13528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal and systemic atheroemboli (also called cholesterol crystal emboli) usually affect older patients with diffuse erosive atherosclerosis. Cholesterol crystal embolization occurs when portions of an atherosclerotic plaque break off and embolize distally, resulting in partial or total occlusion of multiple small arteries (or glomerular arterioles), leading to tissue or organ ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical issues related to renal atheroemboli will be reviewed here. Discussions of cholesterol crystal embolization in general and thromboembolic renal infarction are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=see_link\">",
"     \"Diagnosis and treatment of renal infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atheroembolization is a complication of severe atherosclerosis. Thus, risk factors for atheroembolic disease, such as older age, male sex, diabetes, arterial hypertension, hypercholesterolemia, and cigarette smoking, are the same as for the development of atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2-7\">",
"     2-7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=see_link&amp;anchor=H2#H2\">",
"     \"Overview of the risk equivalents and established risk factors for cardiovascular disease\", section on 'Established risk factors for atherosclerotic CVD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6294037\">",
"    <span class=\"h2\">",
"     Inciting events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once formed, an atherosclerotic plaque may be disrupted by a variety of inciting events, producing cholesterol crystal emboli. These inciting events can be classified broadly into the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Iatrogenic event, usually induced by angiography, cardiovascular surgery, or anticoagulation",
"     </li>",
"     <li>",
"      Spontaneous event, induced by hemodynamic stress",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cholesterol crystal embolization is iatrogenic in more than 70 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. It is often seen following manipulation of the aorta or other large arteries during angiography, angioplasty, or cardiovascular surgery. Mechanical aortic trauma, induced by radiological catheters or vessel",
"    <span class=\"nowrap\">",
"     manipulation/clamping,",
"    </span>",
"    causing plaque disruption, has a key role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2-10\">",
"     2-10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Angiography is the most common triggering event, accounting for as many as 80 percent of iatrogenic cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The incidence of clinically apparent atheroemboli after angiography has not been well defined. The best risk estimates are summarized here:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary angiography is the most common angiographic procedure causing embolism, associated with an incidence varying from 0.06 to 1.8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/6,11-13\">",
"       6,11-13",
"      </a>",
"      ]. As an example, the incidence of atheroembolism following diagnostic cardiac catheterization was evaluated in a prospective study that included 1786 consecutive patients; clinical atheroembolism (cutaneous or renal) was diagnosed in 25 (1.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/6\">",
"       6",
"      </a>",
"      ]. Sixteen patients (0.9 percent) developed acute kidney injury that was thought to be due to renal atheroembolism rather than contrast nephropathy since it persisted for at least two weeks. However, not all patients with acute kidney injury had other evidence of peripheral embolization. The risk may be lower with a brachial rather than an iliofemoral approach since most atherosclerotic plaques are in the abdominal aorta [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link&amp;anchor=H31#H31\">",
"       \"Complications of diagnostic cardiac catheterization\", section on 'Renal atheroemboli'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who undergo renal angiography for suspected atherosclerotic renal artery stenosis often have diffuse atherosclerosis and are at especially high risk. A summary of reported studies of such patients suggests an overall incidence of about 2 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has also been suggested that treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , or thrombolytic agents may cause atheroemboli, perhaps because anticoagulation may interfere with the healing of ulcerated atheromatous plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/3,7,15-17\">",
"     3,7,15-17",
"    </a>",
"    ]. However, anticoagulant-associated atheroembolism is uncommon, even in patients with severe aortic plaque (0.7 to 1 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In addition, most patients with atheroemboli associated with anticoagulation have a second potential trigger, usually recent angiography. Anticoagulation is the sole inciting event in only 7 percent of such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemodynamic stress leading to spontaneous embolization was the most common form in historical reports [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/20-23\">",
"     20-23",
"    </a>",
"    ]. However, as noted, most cases are now related to iatrogenic triggers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol crystal embolization to the kidney typically produces a subacute kidney injury observed several weeks or more after a possible inciting event [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/10\">",
"     10",
"    </a>",
"    ]. Severe hypertension may also be present. Less commonly, acute kidney injury occurring within one to two weeks after the inciting event may be seen, usually in association with massive embolization. Patients with renal atheroemboli are typically older (mean age 71 to 72 years in two large series) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7,8\">",
"     7,8",
"    </a>",
"    ], have a bland urine sediment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/3,7,24,25\">",
"     3,7,24,25",
"    </a>",
"    ], and have may have peripheral eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, kidney injury due to atheroemboli is not the most common presentation; rather, it is often found after the patient has presented in some other way. This is likely because, when it occurs, atheroembolism is ubiquitous, affecting varied vascular distributions. Thus, renal disease from atheroembolism is part of a multisystem disorder. The clinical presentation is more frequently related to atheroembolization of the skin (producing \"blue toe syndrome\" (",
"    <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"     picture 1",
"    </a>",
"    ) or livedo reticularis (",
"    <a class=\"graphic graphic_picture graphicRef79545 \" href=\"UTD.htm?13/33/13841\">",
"     picture 2",
"    </a>",
"    )), mesentery (producing intestinal ischemia, gastrointestinal bleeding, or pancreatitis),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    central nervous system (producing transient ischemic attack, confusion, or visual symptoms). Presenting symptoms may also be subtle and nonspecific, such as fever, myalgias, headache, and weight loss. In addition, patients at risk for atheroembolism are not routinely monitored for worsening kidney function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Kidney injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atheroembolism is not uncommon as a cause of acute kidney injury in elderly patients. This was illustrated in a series of 259 patients over the age of 60 years who underwent renal biopsy for acute kidney injury; 7 percent had atheroembolic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The renal manifestations of atheroembolic disease are usually different from those seen with clot emboli. Clot emboli primarily occur in patients with atrial arrhythmias or a prior myocardial infarction. They tend to produce complete arterial occlusion and renal infarction, leading to flank pain, hematuria, and an elevated lactate dehydrogenase with relatively normal transaminases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=see_link\">",
"     \"Diagnosis and treatment of renal infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    By comparison, atheroemboli are typically nondistensible and irregularly shaped; as a result, they tend to produce incomplete occlusion with secondary ischemic atrophy rather than renal infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/3\">",
"     3",
"    </a>",
"    ]. With time, a foreign body reaction often ensues, causing intimal proliferation, giant cell formation, and further narrowing of the vascular lumen [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ]. This reaction presumably contributes to the progressive decline in renal function that often occurs for three to eight weeks after the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of this pathogenic process, when combined with varying amounts of cholesterol embolization, is three somewhat different clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,4,7,28,29\">",
"     2,4,7,28,29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marked renal impairment with an acute onset, seen within one to two weeks of a clear inciting event, is most frequently due to massive embolization.",
"     </li>",
"     <li>",
"      The most common presentation of the disease is subacute kidney injury, in which progressive renal dysfunction occurs in staggered steps, separated by periods of stable kidney function (often referred to as a \"staircase pattern\"). In this setting, renal impairment is usually observed several weeks or more after a possible insult; others, however, present with uremia and no clear precipitating event. This presentation is probably due to some combination of recurrent embolization and foreign-body reaction.",
"     </li>",
"     <li>",
"      The least common presentation is the patient with chronic stable renal impairment and clinical features similar to those with ischemic nephropathy (due to bilateral renal artery stenosis) and nephrosclerosis, which frequently coexist with cholesterol emboli. The role of cholesterol embolization in patients with ischemic nephropathy and nephrosclerosis is somewhat unclear. Many such patients are misdiagnosed because the crystal embolization is clinically silent (ie, extrarenal signs are frequently absent) and renal or skin biopsy is not performed. If a biopsy is performed, evidence for cholesterol embolization, which can be patchy, may be absent. The presence and clinical consequences of intimal proliferation and vascular-lumen narrowing are probably common features of these disease processes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Urinary findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The urinalysis in patients with renal atheroemboli is typically benign with few cells or casts, a finding consistent with ischemic atrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/3,7,24,25\">",
"     3,7,24,25",
"    </a>",
"    ]. Proteinuria is usually not a prominent feature, except in patients with underlying diabetic nephropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/8\">",
"     8",
"    </a>",
"    ]; however, nephrotic-range proteinuria (as high as 11",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    has been rarely reported [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,25,30\">",
"     2,25,30",
"    </a>",
"    ]. Some patients have an active urinary sediment, including hematuria and, rarely, red cell casts. In this setting, an acute glomerulonephritis or vasculitis may be suspected, particularly if there are extrarenal manifestations [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Evaluation and diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Eosinophiluria also may be seen if the urine sediment is examined with Hansel's stain soon after the renal atheroemboli [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/32\">",
"     32",
"    </a>",
"    ]. One report of 52 patients noted eosinophiluria in only 14 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ]. However, many of these patients may have been evaluated after the acute phase, a time at which eosinophil activation would have ceased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Eosinophilia and hypocomplementemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other abnormalities that commonly occur during the acute phase are eosinophilia and hypocomplementemia; these changes may reflect immunologic activation at the surface of the exposed atheroemboli [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/28,33,34\">",
"     28,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 354 patients, 238 (67 percent) had an eosinophil count &gt;500",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypocomplementemia has been reported in 39 percent of patients in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/23\">",
"       23",
"      </a>",
"      ]. However, this finding has not always been confirmed by other reports [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of renal atheroemboli requires a high index of suspicion and knowledge of the associated risk factors. A clinical diagnosis can be made when a potential inciting event (usually angiography) is followed by the delayed onset of kidney injury (typically several weeks or longer rather than hours or days), particularly when there are signs of extrarenal atheroemboli. Renal biopsy is regarded as the definitive method for diagnosis. Alternatively, biopsy of a skin lesion (if present) is a simple, minimally invasive procedure with a high diagnostic yield. Less commonly, histological confirmation may be made in other organs, such as the gastrointestinal track.",
"   </p>",
"   <p>",
"    However, tissue biopsy is",
"    <strong>",
"     not",
"    </strong>",
"    necessary in patients with iatrogenic atheroembolic renal disease presenting with all of the following features of the classical clinical triad:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A precipitating event (such as aortic or coronary angiography)",
"     </li>",
"     <li>",
"      Subacute or acute kidney injury",
"     </li>",
"     <li>",
"      Typical skin findings, such as blue toe syndrome (",
"      <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"       picture 1",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef79545 \" href=\"UTD.htm?13/33/13841\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a biopsy may be deferred in patients with suspected atheroembolic renal disease if retinal cholesterol crystal emboli (Hollenhorst plaques) are present (",
"    <a class=\"graphic graphic_picture graphicRef63740 \" href=\"UTD.htm?23/3/23601\">",
"     picture 3",
"    </a>",
"    ). Like histology, fundoscopy examination may confirm the diagnosis and should never be omitted.",
"   </p>",
"   <p>",
"    Conversely, renal biopsy is crucial for diagnosis of cases with a chronic, smoldering presentation of renal atheroembolization. A tissue sample is also required to make a definitive diagnosis in patients presenting with a spontaneous (rather than iatrogenic) form of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9412009\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The history should identify potential complications of atheroembolic disease, including skin discoloration of the lower extremities; neurological deficits, including amaurosis fugax; and abdominal pain and gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,3,15\">",
"     2,3,15",
"    </a>",
"    ]. Since most cases are associated with an iatrogenic event, the history should also identify previous angiographies, cardiovascular surgeries, or recent initiation of anticoagulation.",
"   </p>",
"   <p>",
"    The physical examination should identify new or worsened arterial hypertension; cyanosis or discrete gangrenous lesions in the toes with intact peripheral pulses (blue toes) (",
"    <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"     picture 1",
"    </a>",
"    ); livedo reticularis; focal neurological deficits; confusion; orange plaques in the retinal arterioles, called Hollenhorst plaques (",
"    <a class=\"graphic graphic_picture graphicRef63740 \" href=\"UTD.htm?23/3/23601\">",
"     picture 3",
"    </a>",
"    ); and gastrointestinal bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9412175\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to serum chemistries and creatinine, patients suspected of having cholesterol crystal embolization should have a complete blood count with differential, serum amylase and lipase (to evaluate for pancreatitis), serum complement levels, and a urinalysis with both examination of the sediment and an evaluation for eosinophiluria with Hansel's stain.",
"   </p>",
"   <p>",
"    Eosinophilia, eosinophiluria, and hypocomplementemia, if present, may suggest atheroemboli. These findings generally resolve within one week [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,32-34\">",
"     2,32-34",
"    </a>",
"    ] and are therefore signs of recent disease. Persistence or recurrence is suggestive of continued atheroembolization. However, these findings are also associated with other renal diseases, including some forms of glomerulonephritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link\">",
"     \"Differential diagnosis and evaluation of glomerular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34418?source=see_link\">",
"     \"The significance of urinary eosinophils\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9412354\">",
"    <span class=\"h2\">",
"     Tissue biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the diagnosis remains in doubt, biopsy of a skin lesion (if present) or the kidney may be required. Although percutaneous renal biopsy produces a relatively small sample, it appears to detect atheroemboli in over 75 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/25\">",
"     25",
"    </a>",
"    ]. The cholesterol crystals within the emboli are dissolved during tissue fixation; what is therefore observed are",
"    <strong>",
"     pathognomonic",
"    </strong>",
"    biconvex, needle-shaped clefts (\"ghosts\") within the occluded vessel (",
"    <a class=\"graphic graphic_picture graphicRef56672 graphicRef68445 \" href=\"UTD.htm?26/2/26665\">",
"     picture 4A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,15,30\">",
"     2,15,30",
"    </a>",
"    ]. The intraluminal lesions are often accompanied by a perivascular inflammatory reaction that may contain eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Focal segmental glomerulosclerosis may also be seen on renal biopsy, especially in patients with heavy proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/30\">",
"     30",
"    </a>",
"    ]. Why this occurs is not clear, but both ischemic injury and hyperfiltration injury in nonischemic nephrons may contribute [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a patient with otherwise unexplained renal failure, the finding of atheroemboli on renal biopsy is virtually diagnostic of at least a contributory role for atheroembolic renal disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renal atheroemboli developing after angiography or vascular surgery has to be differentiated from radiocontrast media-induced or postischemic acute tubular necrosis (ATN). Extrarenal emboli, if present, favor the diagnosis of atheroemboli. In addition, the course of the two disorders is generally different [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients with ATN characteristically have an acute and progressive rise in the serum creatinine concentration within several days of the procedure that then stabilizes and returns to or near the baseline level after a variable period of 4 to 21 days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=see_link\">",
"     \"Renal and patient outcomes after acute tubular necrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, atheroembolic disease directly due to a procedure is typically associated with a subacute decline in renal function that becomes apparent weeks after the procedure. The serum creatinine concentration rises gradually, reaching its peak at three to eight weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ]. Scarring of the arterial lesions or new emboli contribute to the late progression.",
"   </p>",
"   <p>",
"    The diagnosis of renal atheroemboli may be difficult to establish in patients with spontaneous disease, atypical clinical findings,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    multiorgan involvement. Other diseases associated with eosinophilia and eosinophiluria include acute interstitial nephritis and systemic vasculitis. Renal atheroembolic disease can often be distinguished from a systemic vasculitis or interstitial nephritis by urinalysis (the urine sediment is typically bland with atheroembolic disease)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    antineutrophil cytoplasmic antibody (ANCA) testing [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/4\">",
"     4",
"    </a>",
"    ]. As previously mentioned, however, there are some patients with atheroemboli who have an active urine sediment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34418?source=see_link\">",
"     \"The significance of urinary eosinophils\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=see_link\">",
"     \"Classification of and approach to the vasculitides in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for atheroembolic renal disease. Therapeutic modalities are mostly preventive and supportive. General issues related to the medical and surgical therapy of atheroembolic disease are discussed in detail separately. In addition, all patients should be aggressively treated for secondary prevention of cardiovascular disease. These modalities include statins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , blood pressure control, cessation of smoking, and, in patients with diabetes, glycemic control. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=see_link\">",
"     \"Secondary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with atheroembolic disease, secondary prevention relies upon removal of the causes of atheroembolism and prevention of new showers of atheroemboli. Consideration should be given in affected patients to withdrawal of anticoagulation and avoidance or postponement of new radiologic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular surgery procedures, if possible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link&amp;anchor=H1503460#H1503460\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\", section on 'Preventing recurrent embolization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no proven effective medical therapy in patients with atheroembolic renal disease. Observational studies suggest that statin use may be associated with better outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. As an example, a study followed 354 patients with renal atheroembolic disease for a mean of two years; 116 eventually required dialysis, and 102 died [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/8\">",
"     8",
"    </a>",
"    ]. Baseline use of statins was independently associated with a lower risk of developing end-stage or death (relative risk 0.53, 95% CI 0.36 to 0.77).",
"   </p>",
"   <p>",
"    A potential benefit of low-dose steroids has been reported in retrospective series [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/9,35\">",
"     9,35",
"    </a>",
"    ], but this finding was not confirmed in a prospective study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with renal atheroemboli have a poor overall prognosis, which in part reflects the severity of the underlying vascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,7,8\">",
"     2,7,8",
"    </a>",
"    ]. In the study of 354 patients mentioned above, 33 percent of patients developed end-stage renal disease, and 28 percent of patients died after a mean follow-up of two years [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Kidney injury may be followed by partial recovery of renal function. In one study, for example, 24 percent of patients with renal atheroemboli but no other complications, such as sepsis or hypotension, had recovery of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"     2",
"    </a>",
"    ]. Recovery may be due to a number of factors, including resolution of concurrent acute tubular necrosis (ATN) in borderline ischemic areas, the development of collateral flow, or hypertrophy in surviving nephrons [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13528/abstract/2,3,24,28\">",
"     2,3,24,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cholesterol crystal embolization, or atheroembolization, occurs when portions of an atherosclerotic plaque break off and embolize distally, resulting in partial or total occlusion of multiple small arteries leading to tissue or organ ischemia. Cholesterol crystal embolization usually affects older patients with diffuse erosive atherosclerosis. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholesterol crystal embolization is often seen after manipulation of the aorta or other large arteries during arteriography, angioplasty, or surgery, but may also occur spontaneously. Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or thrombolytic agents may increase the risk, but anticoagulant-associated atheroembolism is uncommon. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cholesterol crystal embolization to the kidney typically produces a subacute kidney injury observed several weeks or more after a possible inciting event. Severe hypertension may also be present. However, an increased serum creatinine is not the most common presentation; rather, it is often found after the patient has presented in some other way since atheroembolism is ubiquitous, affecting various vascular beds, and since laboratory studies to monitor for atheroembolic kidney injury are not routinely performed. Thus, the presentation is more frequently related to atheroembolization of the skin (producing \"blue toe syndrome\" (",
"      <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"       picture 1",
"      </a>",
"      ) or livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef79545 \" href=\"UTD.htm?13/33/13841\">",
"       picture 2",
"      </a>",
"      )), mesentery (producing intestinal ischemia, gastrointestinal bleeding, or pancreatitis), and central nervous system (producing transient ischemic attack, confusion, or visual symptoms). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Renal cholesterol crystal embolization can produce an acute decline in kidney function within one to two weeks of an inciting event; more commonly, a subacute presentation, in which progressive renal dysfunction occurs in staggered steps several weeks or more after an insult; or chronic stable renal impairment and clinical features similar to those with ischemic nephropathy due to bilateral renal artery stenosis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Kidney injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The urinalysis is typically benign with few cells or casts, and proteinuria is usually not a prominent feature; however, nephrotic-range proteinuria has been reported. Some patients have an active urine sediment, including hematuria, and, rarely, red cell casts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Urinary findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other laboratory findings include eosinophilia and hypocomplementemia, possibly reflecting immunologic activation at the surface of the exposed atheroemboli. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Eosinophilia and hypocomplementemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A clinical diagnosis of renal atheroemboli can be made when a potential inciting event (usually angiography) is followed by the delayed onset of kidney injury (typically weeks or longer rather than hours or days), particularly when there are signs of extrarenal atheroemboli. Renal or skin biopsy is regarded as the definitive method for diagnosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A tissue biopsy is",
"      <strong>",
"       not",
"      </strong>",
"      necessary in patients with iatrogenic atheroembolic renal disease presenting with all of the following features of the classical clinical triad (see",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A precipitating event (such as aortic or coronary angiography)",
"     </li>",
"     <li>",
"      Subacute or acute kidney injury",
"     </li>",
"     <li>",
"      Typical skin findings, such as blue toe syndrome (",
"      <a class=\"graphic graphic_picture graphicRef58761 \" href=\"UTD.htm?2/15/2289\">",
"       picture 1",
"      </a>",
"      )",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      livedo reticularis (",
"      <a class=\"graphic graphic_picture graphicRef79545 \" href=\"UTD.htm?13/33/13841\">",
"       picture 2",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A biopsy may also be deferred in patients with suspected atheroembolic renal disease if retinal cholesterol crystal emboli (Hollenhorst plaques) are present (",
"      <a class=\"graphic graphic_picture graphicRef63740 \" href=\"UTD.htm?23/3/23601\">",
"       picture 3",
"      </a>",
"      ). Like histology, fundoscopy examination may confirm the diagnosis and should never be omitted. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Conversely, renal biopsy is crucial for diagnosis of cases with a chronic, smoldering form of renal atheroembolization. A tissue sample is also required to make a definitive diagnosis in patients presenting with spontaneous form of the disorder. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9412354\">",
"       'Tissue biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of renal atheroemboli developing after angiography or vascular surgery primarily includes radiocontrast media-induced or postischemic acute tubular necrosis (ATN). These conditions can often be distinguished by the absence or presence of extrarenal emboli and by the clinical course. In addition, the differential diagnosis includes acute interstitial nephritis and systemic vasculitis, particularly in patients with eosinophilia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypocomplementemia. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific therapy for renal atheroembolic disease. All patients should be aggressively treated for secondary prevention of cardiovascular disease. In addition to statins, this approach includes",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      , blood pressure control, cessation of smoking, and, in patients with diabetes, glycemic control. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with renal atheroemboli have a poor overall prognosis, which in part reflects the severity of the underlying vascular disease. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6294562\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and editors would like to thank Dr. Paul Tunick, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tunick PA, Kronzon I. Atheroembolism. In: Vascular Medicine: A Companion to Braunwald's Heart Disease, Creager M, Dzau VJ, Loscalzo J (Eds), Elsevier, Philadelphia 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/2\">",
"      Thadhani RI, Camargo CA Jr, Xavier RJ, et al. Atheroembolic renal failure after invasive procedures. Natural history based on 52 histologically proven cases. Medicine (Baltimore) 1995; 74:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/3\">",
"      Mannesse CK, Blankestijn PJ, Man in 't Veld AJ, Schalekamp MA. Renal failure and cholesterol crystal embolization: a report of 4 surviving cases and a review of the literature. Clin Nephrol 1991; 36:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/4\">",
"      Scolari F, Tardanico R, Zani R, et al. Cholesterol crystal embolism: A recognizable cause of renal disease. Am J Kidney Dis 2000; 36:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/5\">",
"      Modi KS, Rao VK. Atheroembolic renal disease. J Am Soc Nephrol 2001; 12:1781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/6\">",
"      Fukumoto Y, Tsutsui H, Tsuchihashi M, et al. The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study. J Am Coll Cardiol 2003; 42:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/7\">",
"      Scolari F, Ravani P, Gaggi R, et al. The challenge of diagnosing atheroembolic renal disease: clinical features and prognostic factors. Circulation 2007; 116:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/8\">",
"      Scolari F, Ravani P, Pola A, et al. Predictors of renal and patient outcomes in atheroembolic renal disease: a prospective study. J Am Soc Nephrol 2003; 14:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/9\">",
"      Belenfant X, Meyrier A, Jacquot C. Supportive treatment improves survival in multivisceral cholesterol crystal embolism. Am J Kidney Dis 1999; 33:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/10\">",
"      Scolari F, Ravani P. Atheroembolic renal disease. Lancet 2010; 375:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/11\">",
"      Johnson LW, Esente P, Giambartolomei A, et al. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. Cathet Cardiovasc Diagn 1994; 31:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/12\">",
"      Saklayen MG, Gupta S, Suryaprasad A, Azmeh W. Incidence of atheroembolic renal failure after coronary angiography. A prospective study. Angiology 1997; 48:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/13\">",
"      Scolari F, Bracchi M, Valzorio B, et al. Cholesterol atheromatous embolism: an increasingly recognized cause of acute renal failure. Nephrol Dial Transplant 1996; 11:1607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/14\">",
"      Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism--a critical review. Am J Kidney Dis 1994; 24:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/15\">",
"      Meyrier A, Buchet P, Simon P, et al. Atheromatous renal disease. Am J Med 1988; 85:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/16\">",
"      Hyman BT, Landas SK, Ashman RF, et al. Warfarin-related purple toes syndrome and cholesterol microembolization. Am J Med 1987; 82:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/17\">",
"      Gupta BK, Spinowitz BS, Charytan C, Wahl SJ. Cholesterol crystal embolization-associated renal failure after therapy with recombinant tissue-type plasminogen activator. Am J Kidney Dis 1993; 21:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/18\">",
"      Tunick PA, Nayar AC, Goodkin GM, et al. Effect of treatment on the incidence of stroke and other emboli in 519 patients with severe thoracic aortic plaque. Am J Cardiol 2002; 90:1320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/19\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/20\">",
"      Baumann DS, McGraw D, Rubin BG, et al. An institutional experience with arterial atheroembolism. Ann Vasc Surg 1994; 8:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/21\">",
"      Sharma PV, Babu SC, Shah PM, Nassoura ZE. Changing patterns of atheroembolism. Cardiovasc Surg 1996; 4:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/22\">",
"      Fine MJ, Kapoor W, Falanga V. Cholesterol crystal embolization: a review of 221 cases in the English literature. Angiology 1987; 38:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/23\">",
"      Lye WC, Cheah JS, Sinniah R. Renal cholesterol embolic disease. Case report and review of the literature. Am J Nephrol 1993; 13:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/24\">",
"      Smith MC, Ghose MK, Henry AR. The clinical spectrum of renal cholesterol embolization. Am J Med 1981; 71:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/25\">",
"      Haqqie SS, Urizar RE, Singh J. Nephrotic-range proteinuria in renal atheroembolic disease: report of four cases. Am J Kidney Dis 1996; 28:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/26\">",
"      Haas M, Spargo BH, Wit EJ, Meehan SM. Etiologies and outcome of acute renal insufficiency in older adults: a renal biopsy study of 259 cases. Am J Kidney Dis 2000; 35:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/27\">",
"      Lessman RK, Johnson SF, Coburn JW, Kaufman JJ. Renal artery embolism: clinical features and long-term follow-up of 17 cases. Ann Intern Med 1978; 89:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/28\">",
"      Colt HG, Begg RJ, Saporito JJ, et al. Cholesterol emboli after cardiac catheterization. Eight cases and a review of the literature. Medicine (Baltimore) 1988; 67:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/29\">",
"      Dalakos TG, Streeten DH, Jones D, Obeid A. \"Malignant\" hypertension resulting from atheromatous embolization predominantly of one kidney. Am J Med 1974; 57:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/30\">",
"      Greenberg A, Bastacky SI, Iqbal A, et al. Focal segmental glomerulosclerosis associated with nephrotic syndrome in cholesterol atheroembolism: clinicopathological correlations. Am J Kidney Dis 1997; 29:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/31\">",
"      RICHARDS AM, ELIOT RS, KANJUH VI, et al. CHOLESTEROL EMBOLISM: A MULTIPLE-SYSTEM DISEASE MASQUERADING AS POLYARTERITIS NODOSA. Am J Cardiol 1965; 15:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/32\">",
"      Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med 1991; 91:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/33\">",
"      Cosio FG, Zager RA, Sharma HM. Atheroembolic renal disease causes hypocomplementaemia. Lancet 1985; 2:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/34\">",
"      Kasinath BS, Lewis EJ. Eosinophilia as a clue to the diagnosis of atheroembolic renal disease. Arch Intern Med 1987; 147:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13528/abstract/35\">",
"      Mann SJ, Sos TA. Treatment of atheroembolization with corticosteroids. Am J Hypertens 2001; 14:831.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7182 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-FDEBE4EB0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13528=[""].join("\n");
var outline_f13_13_13528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6294037\">",
"      Inciting events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Kidney injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Urinary findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Eosinophilia and hypocomplementemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9412009\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9412175\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9412354\">",
"      Tissue biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6294562\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7182\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7182|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/15/2289\" title=\"picture 1\">",
"      Blue toe syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/33/13841\" title=\"picture 2\">",
"      Livedo reticularis - lower extremities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/3/23601\" title=\"picture 3\">",
"      Hollenhorst plaque retinal artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/25/9622\" title=\"picture 4A\">",
"      Renal atheroembolus histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35427\" title=\"picture 4B\">",
"      Renal atheroembolus toluidine blue",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/23/37241?source=related_link\">",
"      Classification of and approach to the vasculitides in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/6/11367?source=related_link\">",
"      Diagnosis and treatment of renal infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/59/39866?source=related_link\">",
"      Overview of the risk equivalents and established risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/28/4553?source=related_link\">",
"      Renal and patient outcomes after acute tubular necrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/39/34418?source=related_link\">",
"      The significance of urinary eosinophils",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_13_13529="Evaluation of diarrhea in children";
var content_f13_13_13529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of diarrhea in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Gary R Fleisher, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Stephen J Teach, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Teresa K Duryea, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/13/13529/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/13/13529/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/13/13529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea refers to the passage of loose or watery stools. The World Health Organization (WHO) defines a case as the passage of three or more loose or watery stools per day [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/1\">",
"     1",
"    </a>",
"    ]. Nevertheless, absolute limits of normalcy are difficult to define; any deviation from the child's usual pattern should arouse some concern (particularly with ill appearance, the passage of blood or mucus, or dehydration) regardless of the actual number of stools or their water content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute infectious gastroenteritis due to viruses accounts for most bouts of diarrhea in developed countries, resulting in more than 1.5 million outpatient visits and 200,000 hospitalizations in the United States annually [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/1\">",
"     1",
"    </a>",
"    ]. However, watery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequent stools may be the initial manifestation of a wide spectrum of acute and chronic disorders (",
"    <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Life-threatening conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of disorders causing diarrhea may be life threatening in children (",
"    <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef78848 \" href=\"UTD.htm?18/44/19150\">",
"     algorithm 1A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/3\">",
"     3",
"    </a>",
"    ]. Particularly urgent are intussusception, hemolytic uremic syndrome (HUS), pseudomembranous colitis, appendicitis, toxic megacolon, and in very young infants, the congenital secretory diarrheas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Intussusception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intussusception is most common from 6 to 12 months of age, and the vast majority of cases occur in the first two years of life. Most children with intussusception develop the sudden onset of intermittent, severe, crampy abdominal pain, accompanied by inconsolable crying and drawing up of the legs toward the abdomen, but some present with bloody diarrhea. The episodes of pain usually occur at 15 to 20 minute intervals. They become more frequent and may be followed initially by emesis of gastric contents. Bilious emesis may develop as the obstruction progresses. Between the painful episodes, the child may behave normally. As a result, initial symptoms can be confused with gastroenteritis. As symptoms progress, increasing lethargy develops, which can be mistaken for meningitis.",
"   </p>",
"   <p>",
"    The attacks also can be separated by periods of apathy followed by vomiting and the passage of \"currant jelly\" stool (representing a mixture of blood and mucus). A sausage-shaped abdominal mass may be felt in the right side of abdomen. The prevalence of blood in the stool is as high as 70 percent if occult blood is included and increases with the duration of symptoms. However, the classically described triad of pain, a palpable sausage-shaped abdominal mass, and currant-jelly stool is seen in less than 15 percent of patients at the time of presentation. Up to 20 percent of young infants have no obvious pain. Patients do not pass blood or mucus or develop an abdominal mass in approximately one-third of cases. Some infants and many older children have pain alone without other signs or symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link\">",
"     \"Intussusception in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hemolytic uremic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic uremic syndrome (HUS), although uncommon, merits consideration in any child with bloody diarrhea, particularly in the first five years of life, because it is a potentially fatal illness. It complicates 6 to 9 percent of enterohemorrhagic E. coli infections with the 0157:H7 strain and usually begins 5 to 10 days after the onset of diarrhea. HUS, which has a sudden onset, is characterized by the triad of (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Microangiopathic hemolytic anemia",
"     </li>",
"     <li>",
"      Thrombocytopenia",
"     </li>",
"     <li>",
"      Acute renal failure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Children typically have a prodromal illness with abdominal pain, vomiting, and diarrhea that precedes the development of HUS by a few days, as a result of which a patient may have no signs of hemolysis or renal failure when seen earlier in the course. The diarrhea and associated gastrointestinal complaints may mimic those of ulcerative colitis, other enteric infections, and appendicitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Pseudomembranous colitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This rare but serious disorder results from an overgrowth of toxin-producing clostridial organisms in the bowel. The typical presentation is acute watery diarrhea with lower abdominal pain, low-grade fever, and leukocytosis, starting during or shortly after antibiotic administration. The course can be fulminant, progressing from diarrhea to toxic megacolon and shock [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/4\">",
"     4",
"    </a>",
"    ]. Community-associated infection with a highly toxigenic strain of Clostridium difficile has been reported in otherwise healthy children who had minimal or no exposure to antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link\">",
"     \"Clostridium difficile infection in children: Clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=see_link&amp;anchor=H5#H5\">",
"     \"Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology\", section on 'Hypervirulent strain (BI/NAP1/027)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Appendicitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appendicitis typically begins with diffuse abdominal pain followed by vomiting, often in association with constipation. The three most predictive clinical features are (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H6656886#H6656886\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Overview'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pain in the right lower quadrant",
"     </li>",
"     <li>",
"      Abdominal wall rigidity",
"     </li>",
"     <li>",
"      Migration of periumbilical pain to the right lower quadrant",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less commonly, appendicitis may cause diarrhea. In a retrospective series of 63 children less than three years of age with appendicitis, 33 percent had diarrhea as an initial symptom. The presumed mechanism for the diarrhea is irritation of the colon by the inflamed appendix. The stools are usually of low volume and with mucus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H6658119#H6658119\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical features by age'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of appendicitis as the cause of diarrhea may be delayed because the classic constellation of findings is absent. This is particularly true in very young children or among patients of any age who have a perforated appendix and a long duration of illness. However, abdominal tenderness will be greater than would be expected with gastroenteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=see_link&amp;anchor=H6658119#H6658119\">",
"     \"Acute appendicitis in children: Clinical manifestations and diagnosis\", section on 'Clinical features by age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Toxic megacolon",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxic megacolon can occur as a complication of Shigella infection, pseudomembranous colitis, Hirschsprung disease, or inflammatory bowel disease. These conditions are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=see_link\">",
"     \"Treatment of ulcerative colitis in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of Shigella infection\", section on 'Toxic megacolon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8630567\">",
"    <span class=\"h3\">",
"     Congenital secretory diarrheas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital secretory diarrheas are characterized by profuse watery diarrhea beginning at or shortly after birth and are rare. They are caused by a variety of inherited disorders that disrupt nutrient digestion, absorption, or transport, enterocyte development and function, or enteroendocrine function (",
"    <a class=\"graphic graphic_table graphicRef73777 \" href=\"UTD.htm?20/7/20606\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of the causes of chronic diarrhea in children\", section on 'Congenital secretory and osmotic diarrheas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Common conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common causes of diarrhea are infections with viruses and bacteria, diarrhea due to a systemic infection other than gastrointestinal, diarrhea associated with antibiotic administration, and feeding related diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By far, the single most common diarrheal disorder seen in the emergency department and in general practice is viral gastroenteritis. In one series of children two months to two years of age, a viral etiology was identified in 60 percent of all cases of diarrhea and in 85 percent of moderately severe and severe episodes [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/5\">",
"       5",
"      </a>",
"      ]. In a prospective case control study that evaluated the infectious etiology of diarrhea in 254 children with a median age younger than two years coming to a pediatric emergency department, a viral etiology was identified in 54 percent of patients while virus isolation only occurred in 5 percent of matched controls [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link\">",
"       \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Extraintestinal infections (such as otitis media, urinary tract infections, and pneumonia) can cause acute diarrhea that is usually mild and self-limited. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=see_link&amp;anchor=H22#H22\">",
"       \"Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications\", section on 'Symptoms and signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotic associated diarrhea (AAD) occurs commonly with many antibiotics, including",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"       amoxicillin",
"      </a>",
"      which is frequently prescribed in pediatrics. In one prospective series, 18 percent of children less than two years of age developed diarrhea associated with antibiotic use [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/7\">",
"       7",
"      </a>",
"      ]. The pathophysiology of AAD is poorly understood, but is likely related to disruption in fecal flora [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Overfeeding (particularly with hyperosmolar fluids) may cause diarrhea as the result of increased osmotic load. Diarrhea may also occur when intake of solid foods is limited (sometimes referred to as \"starvation stools\"). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=see_link&amp;anchor=H16#H16\">",
"       \"Malnutrition in developing countries: Clinical assessment\", section on 'Diarrhea and dehydration'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"       Lactase",
"      </a>",
"      deficiency, when it occurs in younger children, this is usually a transient problem, caused by mucosal injury from an enteric infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/9\">",
"       9",
"      </a>",
"      ]. In older children and adolescents, this may be a primary lactase deficiency (also known as adult-type hypolactasia or lactase nonpersistence), that affects up to 70 percent of normal adults. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=see_link\">",
"       \"Lactose intolerance\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryptosporidium is an intracellular protozoan parasite that is associated with sporadic outbreaks of self-limited diarrhea in immunocompetent hosts, sometimes in relationship to contaminated drinking water; chronic life-threatening illness in immunocompromised patients, especially those with human immunodeficiency virus; and diarrhea and malnutrition in young children in developing countries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis\", section on 'Epidemiology'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Toxic ingestions (such as contaminated food and organophosphates) can cause diarrhea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=see_link\">",
"     \"Food poisoning in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=see_link\">",
"     \"Organophosphate and carbamate poisoning\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of uncommon conditions (",
"    <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"     table 1",
"    </a>",
"    ) can cause diarrhea that is usually chronic. These include primary immunodeficiencies, diarrhea related to HIV infection, food allergies, celiac disease, inflammatory bowel disease, cystic fibrosis, acrodermatitis enteropathica, secretory tumors, endocrine disorders (particularly hyperthyroidism), and neonatal drug withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=see_link&amp;anchor=H8#H8\">",
"     \"Zinc deficiency and supplementation in children and adolescents\", section on 'Acrodermatitis enteropathica'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=see_link\">",
"     \"Clinical characteristics of carcinoid tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=see_link\">",
"     \"Neonatal opioid withdrawal (Neonatal abstinence syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ACUTE DIARRHEA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of historical factors to consider. Among the first is the immune status of the child, as immunocompromise increases the risk for infections with unusual organisms, the prevalence of which varies with the degree of immunosuppression and the nature of the underlying condition.",
"   </p>",
"   <p>",
"    Another feature of the illness to identify is whether the diarrhea is acute or chronic. An acute diarrheal illness is typically defined as a duration of five days or less. Symptoms that have persisted for longer suggest other diagnoses, such as those discussed below. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Chronic diarrhea'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Institutionalized children and those recently returning from developing countries are more likely to have bacterial or parasitic pathogens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=see_link\">",
"     \"Travelers' diarrhea\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A history of recent antibiotic use suggests the possibility of pseudomembranous colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link&amp;anchor=H6#H6\">",
"     \"Clostridium difficile infection in children: Clinical features\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two features of the diarrheal illness, either alone or in combination, that are particularly helpful in sorting through the differential diagnosis are the presence of fever and bloody or mucousy diarrhea. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Algorithmic approach to the patient'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient who requires volume resuscitation must be quickly identified. Clinical evidence of dehydration such as decreased urine output, tachycardia, and dry mucus membranes are already apparent at a deficit of 5 percent of body weight. The most useful signs for predicting a volume deficit of 5 percent or more include delayed capillary refill time greater than two seconds, reduced skin turgor, and deep respirations with or without an increase in respiratory rate, particularly if a combination of these findings is present. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Degree of dehydration'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    In addition to identifying volume depletion, a thorough examination must be performed because systemic, non-enteric infections, particularly otitis media, may cause diarrhea. A palpable mass or peritonitis suggests appendicitis, intussusception or, less commonly, toxic megacolon. Generalized toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock may occur with hemolytic uremic syndrome or with sepsis, such as from Salmonella or staphylococcal toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory testing and imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information gathered from the history and physical examination will suggest useful laboratory tests and imaging studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diarrhea usually results in isotonic volume depletion. Although clinically significant electrolyte disturbances do not occur frequently, children who are ill-appearing or who have significant dehydration requiring intravenous rehydration should have serum electrolytes measured. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A stool culture should be performed in febrile children with frankly bloody or mucousy diarrhea. A bacterial pathogen will be identified in 15 to 20 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Routine cultures of stool are not recommended for nonbloody diarrhea of brief duration in otherwise healthy children. Stool for Clostridium difficile should be sent in patients with bloody diarrhea who have been on antibiotics. Stool for ova and parasites is indicated for children who have traveled to or reside in an endemic area.",
"     </li>",
"     <li>",
"      Viral antigen tests of stool (especially for rotavirus during times of high prevalence) may be helpful in distinguishing acute viral gastroenteritis from a bacterial process, but they are generally not necessary for most patients.",
"     </li>",
"     <li>",
"      Infants and young children with urinary tract infections may have diarrhea. Thus, a urine culture should be obtained in young children at risk for urinary tract infection when diarrhea occurs in a febrile child and no other source of infection is identified. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=see_link&amp;anchor=H10#H10\">",
"       \"Clinical features and diagnosis of urinary tract infections in infants and children older than one month\", section on 'Decision to obtain'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Imaging studies such as abdominal ultrasound, abdominal computed tomography, and air contrast enema may also be helpful in children with diarrhea and findings suggestive of intussusception, and less commonly, appendicitis as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal ultrasound is a noninvasive technique to identify an intussusception. It is also useful in the initial evaluation of appendicitis, particularly in girls where there may be a possibility of ovarian torsion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link&amp;anchor=H11#H11\">",
"       \"Intussusception in children\", section on 'Ultrasonography'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=see_link&amp;anchor=H2#H2\">",
"       \"Acute appendicitis in children: Diagnostic imaging\", section on 'Ultrasonography (US)'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Contrast enema confirms the ultrasound diagnosis and in most cases provides treatment of ileocolic intussusception. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link&amp;anchor=H15#H15\">",
"       \"Intussusception in children\", section on 'Nonoperative reduction'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abdominal computed tomography can provide important diagnostic information in patients who may have a significant intraabdominal process, including appendicitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=see_link&amp;anchor=H9#H9\">",
"       \"Acute appendicitis in children: Diagnostic imaging\", section on 'Computed tomography (CT)'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Algorithmic approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;An algorithmic approach provides clinical guidance to the diagnostic approach of diarrhea in children (",
"    <a class=\"graphic graphic_algorithm graphicRef78848 \" href=\"UTD.htm?18/44/19150\">",
"     algorithm 1A",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef78118 \" href=\"UTD.htm?28/41/29328\">",
"     algorithm 1B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef57713 \" href=\"UTD.htm?30/41/31390\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunocompromised patients are at risk for unusual infections and require a rigorous approach in accordance with protocols specific to the underlying disorder. First, the physician should determine whether the child appears seriously ill (",
"    <a class=\"graphic graphic_algorithm graphicRef78848 \" href=\"UTD.htm?18/44/19150\">",
"     algorithm 1A",
"    </a>",
"    ) or has signs of a surgical abdominal process. A palpable mass or peritonitis suggests appendicitis, intussusception, or, less commonly, toxic megacolon. Generalized toxicity",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shock may occur with hemolytic uremic syndrome and with sepsis, such as from Salmonella [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/10\">",
"     10",
"    </a>",
"    ] or staphylococcal toxic shock syndrome. Seizures may be seen with shigellosis, occasionally before the onset of diarrhea. Profuse diarrhea in associate with excessive salivation, lacrimation, and urination suggests organophosphate ingestion. Immunocompromised patients (",
"    <a class=\"graphic graphic_algorithm graphicRef78118 \" href=\"UTD.htm?28/41/29328\">",
"     algorithm 1B",
"    </a>",
"    ) are at risk for unusual infections and require a rigorous approach in accordance with protocols specific to the underlying disorder.",
"   </p>",
"   <p>",
"    Next, the physician focuses on those with acute diarrhea (",
"    <a class=\"graphic graphic_algorithm graphicRef78118 \" href=\"UTD.htm?28/41/29328\">",
"     algorithm 1B",
"    </a>",
"    ), as these patients are more likely to require a diagnostic or therapeutic intervention. Fever and bloody or mucousy diarrhea, either alone or in combination, are particularly helpful in sorting through the differential diagnosis (",
"    <a class=\"graphic graphic_algorithm graphicRef78118 \" href=\"UTD.htm?28/41/29328\">",
"     algorithm 1B",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood is seen in the stool of up to 10 percent of children with diarrhea. In most cases, the blood appears in small quantities as drops on the surface of the stool and should not be construed as ominous.",
"     </li>",
"     <li>",
"      A small percentage of children with diarrhea, however, have more profuse rectal bleeding. Particularly in these patients, one must exclude life-threatening disorders such as intussusception, HUS, and pseudomembranous colitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=see_link&amp;anchor=H6#H6\">",
"       \"Diagnostic approach to lower gastrointestinal bleeding in children\", section on 'Causes of bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucousy diarrhea, with or without blood, suggests bacterial enteritis [",
"      <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Febrile with non-bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of fever in an immunocompetent child with diarrhea is the hallmark of infection. Most febrile children with nonbloody diarrhea have viral enteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=see_link\">",
"     \"Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Afebrile with non-bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many afebrile children with nonbloody diarrhea will also have viral enteritis. For those taking antibiotics, such as",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/49/34583?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , the diarrhea may be related to the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Overfeeding may cause diarrhea during the first 6 to 12 months of life. The tip-off to this diagnosis is the history of excessive fluid intake in an overweight child [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Febrile with bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Febrile children with bloody",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mucousy diarrhea typically have infectious bacterial enteritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=see_link&amp;anchor=H10#H10\">",
"     \"Epidemiology and causes of acute diarrhea in developed countries\", section on 'Bloody diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible exceptions include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pseudomembranous colitis is an important consideration in children with bloody diarrhea who have also received antibiotic therapy, especially if systemic toxicity, abdominal distension, and gross blood in the stools are present. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link&amp;anchor=H6#H6\">",
"       \"Clostridium difficile infection in children: Clinical features\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Amebiasis merits consideration in children or immigrants from endemic areas (eg, India, Africa, Mexico, Central and South America) and, less commonly, among travelers to these regions. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=see_link&amp;anchor=H17143399#H17143399\">",
"       \"Intestinal Entamoeba histolytica amebiasis\", section on 'Epidemiology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An occasional child with inflammatory bowel disease may present with an initial episode of acute, bloody diarrhea. In most of these cases, the physician can elicit a preceding history of weight loss or recurrent abdominal pain. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical features and diagnosis of inflammatory bowel disease in children and adolescents\", section on 'Symptoms suggesting colitis'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Afebrile with bloody diarrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Afebrile children with bloody diarrhea represent the most worrisome category because most patients with intussusception, hemolytic-uremic syndrome (HUS), and pseudomembranous colitis have this symptom constellation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intussusception should be considered carefully in any child less than one year of age with grossly bloody diarrhea that does not appear to have an infectious cause. A history of severe, colicky abdominal pain in a lethargic child warrants an abdominal ultrasound or contrast enema. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=see_link&amp;anchor=H9#H9\">",
"       \"Intussusception in children\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bloody diarrhea with pallor, purpura, elevated serum blood urea nitrogen or creatinine, and hematuria point to HUS. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Clinical and laboratory manifestations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Prior antibiotic therapy raises the possibility of pseudomembranous colitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=see_link&amp;anchor=H6#H6\">",
"       \"Clostridium difficile infection in children: Clinical features\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common diagnosis, infectious bacterial enteritis, should be made only after exclusion of the more serious disorders by history, physical examination, and occasionally, laboratory or imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Therapeutic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with life-threatening causes for diarrhea warrant specific therapy dictated by the underlying condition. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Life-threatening conditions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Parenteral fluid resuscitation with an isotonic solution (eg, normal saline) should be initiated promptly in children with moderate to severe dehydration or circulatory compromise and may be particularly important in preventing oliguric renal failure in those with patients with hemolytic uremic syndrome. Patients with toxic megacolon and intussusception may also have significant ongoing third space losses that must be replaced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\", section on 'Fluid'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=see_link\">",
"     \"Treatment of hypovolemia (dehydration) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most children with diarrhea will not require intravenous hydration. Treatment with oral rehydration solutions should be encouraged as the first line therapy for both rehydration and maintenance therapy in patients who have mild to moderate dehydration and can drink. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=see_link\">",
"     \"Oral rehydration therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotics should not be used for children with acute bloody diarrhea unless a specific pathogen has been isolated. Antibiotic therapy may be a risk factor for the development of hemolytic uremic syndrome in patients with bloody diarrhea due to E. Coli O157:H7, which may be indistinguishable from bloody diarrhea seen with other non E Coli bacterial etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/13/13529/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Probiotics refer to products derived from food sources, especially cultured milk products. The list of such microorganisms continues to grow and includes a variety of different strains of bacteria. Probiotics appear to have only a modest effect on recovery from infectious diarrhea. Systematic reviews also suggest that probiotics (including various bacterial species and the yeast S. boulardii) are effective in reducing the incidence of diarrhea in patients who are taking antibiotics. However, discordant data have been published and there is little detailed information regarding the optimal dose or timing of supplementation or the effects on subgroups of patients. The use of probiotics for these indications is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link&amp;anchor=H7#H7\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Antibiotic-associated diarrhea'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link&amp;anchor=H8#H8\">",
"     \"Probiotics for gastrointestinal diseases\", section on 'Infectious diarrhea'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with infectious diarrhea have mild to moderate dehydration and can be managed as outpatients after receiving appropriate assessment and oral rehydration therapy.",
"   </p>",
"   <p>",
"    Hospital admission is warranted in children with any one of the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diagnosis of or strong clinical suspicion for a life-threatening cause of diarrhea, such as HUS or other systemic illnesses (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Life-threatening conditions'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Severe dehydration or significant electrolyte abnormalities upon presentation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=see_link&amp;anchor=H4#H4\">",
"       \"Clinical assessment and diagnosis of hypovolemia (dehydration) in children\", section on 'Degree of dehydration'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Lack of improvement with rehydration",
"     </li>",
"     <li>",
"      Continued copious diarrhea that is likely to lead to recurrent dehydration if intravenous replacement of ongoing losses does not occur",
"     </li>",
"     <li>",
"      Inability to drink &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Persistent symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child who returns with the persistence of an acute diarrheal illness, initially presumed to be viral in origin and with no evidence of malnutrition or dehydration, often can be managed without an extensive evaluation. Common causes, in addition to persistent viral infection, are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bacterial infections",
"     </li>",
"     <li>",
"      Parasitic infections",
"     </li>",
"     <li>",
"      Starvation stools in the child who inadvertently has been continued on a clear liquid diet for several days",
"     </li>",
"     <li>",
"      Secondary",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/62/14306?source=see_link\">",
"       lactase",
"      </a>",
"      deficiency following viral enteritis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A stool culture should be obtained, and testing for clostridial toxin is indicated in children who have had recent antibiotic therapy. Gradual refeeding is recommended if the child has remained on a clear liquid diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     CHRONIC DIARRHEA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A brief initial evaluation of the child with chronic diarrhea in the acute setting (eg, emergency department) is described below (",
"    <a class=\"graphic graphic_algorithm graphicRef57713 \" href=\"UTD.htm?30/41/31390\">",
"     algorithm 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"     table 1",
"    </a>",
"    ). A more comprehensive diagnostic approach to chronic diarrheal diseases in developed countries is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the developing world, chronic diarrhea typically is associated with serial enteric infections and malnutrition. This common pathophysiology calls for a distinct algorithmic approach to diagnosis and treatment, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"     \"Persistent diarrhea in children in developing countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following historical features may indicate serious underlying disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A history of delayed passage of meconium, constipation since birth, and abdominal distension are compatible with Hirschsprung disease.",
"     </li>",
"     <li>",
"      Malabsorptive stools and respiratory infections suggest cystic fibrosis.",
"     </li>",
"     <li>",
"      Failure to thrive, thrush, and pneumonia occur in association with human immunodeficiency virus (HIV) infection.",
"     </li>",
"     <li>",
"      A prolonged history of diarrhea (&gt;1 month) points to inflammatory bowel disease, particularly if the diarrhea is bloody, or to irritable bowel syndrome, malabsorption (eg, cystic fibrosis), immunodeficiency, secretory disorders, or anatomic abnormalities (eg, Hirschsprung disease). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=see_link\">",
"       \"Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In those children with diarrhea of intermediate duration (one to four weeks), the physician should consider an appendiceal abscess (particularly with the finding of abdominal tenderness or a history of abdominal pain), bacterial enteritis, and parasitic infestations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child's overall state of nutrition may indicate the severity and or duration of symptoms. Physical findings associated with inflammatory bowel disease such as weight loss, arthritis or aphthous ulcers may point to that diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A stool culture diagnoses serious infections of the gastrointestinal tract and provides a head start on the evaluation for the physician who subsequently sees the child. Parasitic infections merit consideration as well, particularly in individuals with a history of recent immigration, travel to an underdeveloped country, or backcountry camping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Algorithmic approach to the patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;A child with chronic diarrhea who presents in an acute care setting is infrequently seriously ill. The evaluation usually requires a period of observation and ancillary studies rather than urgent diagnostic and therapeutic intervention. Urgent conditions are suggested by a history of bloody diarrhea or the physical finding of abdominal tenderness (",
"    <a class=\"graphic graphic_algorithm graphicRef57713 \" href=\"UTD.htm?30/41/31390\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Appendicitis and bacterial enteritis are urgent conditions that must be identified. Other less urgent diagnoses include Hirschsprung disease or cystic fibrosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=see_link\">",
"     \"Congenital aganglionic megacolon (Hirschsprung disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=see_link\">",
"     \"Cystic fibrosis: Overview of gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"     \"Overview of the causes of chronic diarrhea in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"     \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Disposition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The child with chronic diarrhea who is well-appearing and tolerates oral fluids can be managed as an outpatient. The key factor in successfully diagnosing the etiology of the diarrhea is good follow-up with a primary care provider.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=see_link\">",
"       \"Patient information: Diarrhea in children (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=see_link\">",
"       \"Patient information: Acute diarrhea in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to the evaluation of acute diarrhea is summarized in the algorithms (",
"      <a class=\"graphic graphic_algorithm graphicRef78848 graphicRef78118 \" href=\"UTD.htm?0/0/8\">",
"       algorithm 1A-B",
"      </a>",
"      ). The table summarizes the causes of diarrhea, highlighting the most common and the most life threatening pediatric conditions (",
"      <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Two features of acute diarrheal illness, either alone or in combination, that are particularly helpful in sorting through the differential diagnosis are the presence of fever and bloody or mucousy diarrhea. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'History'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Algorithmic approach to the patient'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The patient with acute diarrhea who requires volume resuscitation must be quickly identified. Clinical evidence of dehydration such as decreased urine output, tachycardia, and dry mucus membranes are already apparent at a deficit of 5 percent of body weight. The most useful signs for predicting a volume deficit of 5 percent or more include delayed capillary refill time greater than two seconds, reduced skin turgor, and deep respirations with or without an increase in respiratory rate, particularly if a combination of these findings is present. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition to identifying volume depletion, a thorough examination must be performed because systemic, non-enteric infections, particularly otitis media, may cause acute diarrhea. A palpable mass or peritonitis suggests appendicitis, intussusception or, less commonly, toxic megacolon. Generalized toxicity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shock may occur with hemolytic uremic syndrome or with sepsis, such as from Salmonella or staphylococcal toxic shock syndrome. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ancillary studies in children with acute diarrhea are based upon a careful history and physical examination. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory testing and imaging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A brief initial evaluation of the child with chronic diarrhea in the acute setting (eg, emergency department) is described above (",
"      <a class=\"graphic graphic_algorithm graphicRef57713 \" href=\"UTD.htm?30/41/31390\">",
"       algorithm 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef58814 \" href=\"UTD.htm?24/0/24589\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Chronic diarrhea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A more comprehensive diagnostic approach to chronic diarrheal diseases in developed and developing countries is discussed in greater detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=see_link\">",
"       \"Overview of the causes of chronic diarrhea in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=see_link\">",
"       \"Approach to the diagnosis of chronic diarrhea in children in developed countries\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=see_link\">",
"       \"Persistent diarrhea in children in developing countries\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/1\">",
"      King CK, Glass R, Bresee JS, et al. Managing acute gastroenteritis among children: oral rehydration, maintenance, and nutritional therapy. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/2\">",
"      Cohen MB. Etiology and mechanisms of acute infectious diarrhea in infants in the United States. J Pediatr 1991; 118:S34.",
"     </a>",
"    </li>",
"    <li>",
"     Fleisher GR. Diarrhea. In: Textbook of Pediatric Emergency Medicine, 6th edition, Fleisher GR, Ludwig S.  (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia, PA 2010. p.212.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/4\">",
"      Prince AS, Neu HC. Antibiotic-associated pseudomembranous colitis in children. Pediatr Clin North Am 1979; 26:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/5\">",
"      Pang XL, Honma S, Nakata S, Vesikari T. Human caliciviruses in acute gastroenteritis of young children in the community. J Infect Dis 2000; 181 Suppl 2:S288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/6\">",
"      Denno DM, Shaikh N, Stapp JR, et al. Diarrhea etiology in a pediatric emergency department: a case control study. Clin Infect Dis 2012; 55:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/7\">",
"      Turck D, Bernet JP, Marx J, et al. Incidence and risk factors of oral antibiotic-associated diarrhea in an outpatient pediatric population. J Pediatr Gastroenterol Nutr 2003; 37:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/8\">",
"      Surawicz CM. Antibiotic-associated diarrhea in children: how many dirty diapers? J Pediatr Gastroenterol Nutr 2003; 37:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/9\">",
"      Heyman MB, Committee on Nutrition. Lactose intolerance in infants, children, and adolescents. Pediatrics 2006; 118:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/10\">",
"      Torrey S, Fleisher G, Jaffe D. Incidence of Salmonella bacteremia in infants with Salmonella gastroenteritis. J Pediatr 1986; 108:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/11\">",
"      Finkelstein JA, Schwartz JS, Torrey S, Fleisher GR. Common clinical features as predictors of bacterial diarrhea in infants. Am J Emerg Med 1989; 7:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/12\">",
"      Gupta DN, Sircar BK, Sengupta PG, et al. Epidemiological and clinical profiles of acute invasive diarrhoea with special reference to mucoid episodes: a rural community-based longitudinal study. Trans R Soc Trop Med Hyg 1996; 90:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/13\">",
"      Dutta P, Mitra U, Saha DR, et al. Mucoid presentation of acute enterocolitis in children: a hospital-based case-control study. Acta Paediatr 1999; 88:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/14\">",
"      Issenman RM, Hewson S, Pirhonen D, et al. Are chronic digestive complaints the result of abnormal dietary patterns? Diet and digestive complaints in children at 22 and 40 months of age. Am J Dis Child 1987; 141:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/13/13529/abstract/15\">",
"      Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000; 342:1930.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6456 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-9C35C7E240-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13529=[""].join("\n");
var outline_f13_13_13529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Life-threatening conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Intussusception",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hemolytic uremic syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Pseudomembranous colitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Appendicitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Toxic megacolon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8630567\">",
"      - Congenital secretory diarrheas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Common conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ACUTE DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory testing and imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Algorithmic approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Febrile with non-bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Afebrile with non-bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Febrile with bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Afebrile with bloody diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Therapeutic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Persistent symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      CHRONIC DIARRHEA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Algorithmic approach to the patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Disposition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6456\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6456|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?18/44/19150\" title=\"algorithm 1A\">",
"      Diarrhea seriously ill child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?28/41/29328\" title=\"algorithm 1B\">",
"      Diarrhea acute child",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/41/31390\" title=\"algorithm 2\">",
"      Diarrhea chronic child",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6456|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/0/24589\" title=\"table 1\">",
"      Etiology of diarrhea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/7/20606\" title=\"table 2\">",
"      Genetic causes of congenital diarrhea",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/3/32826?source=related_link\">",
"      Acute appendicitis in children: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/61/19416?source=related_link\">",
"      Acute appendicitis in children: Diagnostic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/60/29642?source=related_link\">",
"      Acute otitis media in children: Epidemiology, microbiology, clinical manifestations, and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/43/35511?source=related_link\">",
"      Approach to the diagnosis of chronic diarrhea in children in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/33/3607?source=related_link\">",
"      Clinical assessment and diagnosis of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/25/27034?source=related_link\">",
"      Clinical features and diagnosis of inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21129?source=related_link\">",
"      Clinical features and diagnosis of urinary tract infections in infants and children older than one month",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/40/38535?source=related_link\">",
"      Clinical manifestations and diagnosis of Shigella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/57/14232?source=related_link\">",
"      Clinical manifestations, diagnosis and treatment of enterohemorrhagic Escherichia coli (EHEC) infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/16/11528?source=related_link\">",
"      Clostridium difficile infection in children: Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/22/16745?source=related_link\">",
"      Clostridium difficile infection in children: Microbiology, pathogenesis, and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41848?source=related_link\">",
"      Congenital aganglionic megacolon (Hirschsprung disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/15/19706?source=related_link\">",
"      Cystic fibrosis: Overview of gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/52/29513?source=related_link\">",
"      Diagnostic approach to lower gastrointestinal bleeding in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/46/26345?source=related_link\">",
"      Epidemiology and causes of acute diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/13/3288?source=related_link\">",
"      Epidemiology and environmental factors in inflammatory bowel disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/40/13961?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of cryptosporidiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/56/14216?source=related_link\">",
"      Epidemiology, pathogenesis, clinical presentation and diagnosis of viral gastroenteritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/2/16426?source=related_link\">",
"      Food poisoning in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/20/35145?source=related_link\">",
"      Intussusception in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/32/5641?source=related_link\">",
"      Lactose intolerance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/31/32248?source=related_link\">",
"      Malnutrition in developing countries: Clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/57/39833?source=related_link\">",
"      Neonatal opioid withdrawal (Neonatal abstinence syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/15/18681?source=related_link\">",
"      Oral rehydration therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/25/33176?source=related_link\">",
"      Organophosphate and carbamate poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/5/5210?source=related_link\">",
"      Overview of the causes of chronic diarrhea in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/1/27?source=related_link\">",
"      Patient information: Acute diarrhea in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?33/34/34338?source=related_link\">",
"      Patient information: Diarrhea in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/37/43609?source=related_link\">",
"      Persistent diarrhea in children in developing countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29145?source=related_link\">",
"      Travelers' diarrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/59/30649?source=related_link\">",
"      Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/17/17688?source=related_link\">",
"      Treatment of hypovolemia (dehydration) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/34/4650?source=related_link\">",
"      Treatment of ulcerative colitis in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29753?source=related_link\">",
"      Zinc deficiency and supplementation in children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_13_13530="Menstrual cycle PI";
var content_f13_13_13530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79496&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 575px\">",
"   <div class=\"ttl\">",
"    Menstrual cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 555px; height: 712px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13530=[""].join("\n");
var outline_f13_13_13530=null;
var title_f13_13_13531="Melatonin timing";
var content_f13_13_13531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50327&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Timing of melatonin intake",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Direction of travel",
"       </td>",
"       <td class=\"subtitle1\">",
"        During travel*",
"       </td>",
"       <td class=\"subtitle1\">",
"        1st evening at destination",
"       </td>",
"       <td class=\"subtitle1\">",
"        2nd",
"       </td>",
"       <td class=\"subtitle1\">",
"        3rd",
"       </td>",
"       <td class=\"subtitle1\">",
"        4th",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Eastward",
"         </strong>",
"        </p>",
"        <p>",
"         eg, US to Europe",
"        </p>",
"       </td>",
"       <td>",
"        After it gets dark, 30 min before target bedtime",
"       </td>",
"       <td colspan=\"4\">",
"        After dark, 30 min before local bedtime",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Westward",
"         </strong>",
"        </p>",
"        <p>",
"         eg, Europe to US",
"        </p>",
"        <p>",
"         US to Australia",
"        </p>",
"       </td>",
"       <td>",
"        [Not needed]",
"       </td>",
"       <td colspan=\"4\">",
"        After dark, 30 min before local bedtime",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * If travel involves more than one night, take one dose on each travel night.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13531=[""].join("\n");
var outline_f13_13_13531=null;
var title_f13_13_13532="Mod NIH risk strat for GIST incl rupture";
var content_f13_13_13532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F85938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F85938&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Modified NIH risk stratification criteria for GIST with rupture included",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk category",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor size (cm)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mitotic index (per 50 HPFs)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary tumor site",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very low risk",
"       </td>",
"       <td>",
"        &lt;2.0",
"       </td>",
"       <td>",
"        &le;5",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low risk",
"       </td>",
"       <td>",
"        2.1 to 5.0",
"       </td>",
"       <td>",
"        &le;5",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Intermediate risk",
"       </td>",
"       <td>",
"        2.1 to 5.0",
"       </td>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        Gastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &lt;5.0",
"       </td>",
"       <td>",
"        6 to 10",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.1 to 10.0",
"       </td>",
"       <td>",
"        &le;5",
"       </td>",
"       <td>",
"        Gastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        High risk",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Tumor rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;10 cm",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any",
"       </td>",
"       <td>",
"        &gt;10",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;5.0",
"       </td>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        Any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2.1 to 5.0",
"       </td>",
"       <td>",
"        &gt;5",
"       </td>",
"       <td>",
"        Nongastric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5.1 to 10.0",
"       </td>",
"       <td>",
"        &le;5",
"       </td>",
"       <td>",
"        Nongastric",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HPF: high power fields.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol 2008; 39:1411. Table used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13532=[""].join("\n");
var outline_f13_13_13532=null;
var title_f13_13_13533="Differential dx COPD";
var content_f13_13_13533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51974&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of COPD",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggestive Features*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        COPD",
"       </td>",
"       <td>",
"        Onset in mid-life; onset in early adulthood should prompt suspicion for alpha-1 antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms slowly progressive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Long smoking history, although can occur in nonsmokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dyspnea during exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Largely irreversible airflow limitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        Asthma",
"       </td>",
"       <td>",
"        Onset early in life (often childhood)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms vary from day to day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms at night/early morning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergy, rhinitis, and/or eczema also present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Largely reversible airflow limitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Central airway obstruction (eg, bronchogenic or metastatic cancer, lymphadenopathy, scarring from&nbsp;endotracheal tube)&nbsp;",
"       </td>",
"       <td>",
"        Monophonic wheeze or stridor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Variable inspiratory or fixed slowing on flow volume loop",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph often normal&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway narrowing on three dimensional reconstruction of HRCT scan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Heart failure",
"       </td>",
"       <td>",
"        Fine basilar crackles on auscultation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest&nbsp;radiograph shows dilated heart, pulmonary edema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulmonary function tests typically&nbsp;indicate volume restriction,&nbsp;but airflow limitation can sometimes be seen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Bronchiectasis",
"       </td>",
"       <td>",
"        Large volumes of purulent sputum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Commonly associated with recurrent or persistent bacterial infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coarse crackles on auscultation, clubbing of digits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest radiograph/HRCT shows bronchial dilation, bronchial wall thickening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Tuberculosis",
"       </td>",
"       <td>",
"        Onset all ages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest&nbsp;radiograph shows upper lung zone scarring and/or calcified granulomata",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Positive PPD or IGRA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High local prevalence of tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Obliterative bronchiolitis",
"       </td>",
"       <td>",
"        Onset in younger age, nonsmokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May have history of rheumatoid arthritis or fume exposure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HRCT on expiration shows hypodense areas, mosaic pattern",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Diffuse panbronchiolitis",
"       </td>",
"       <td>",
"        Most patients are male and nonsmokers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Highest prevalence in East Asia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Almost all have chronic sinusitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chest&nbsp;radiograph and HRCT show diffuse small centrilobular nodular opacities and hyperinflation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HRCT: high resolution computed tomography; PPD: purified protein derivative; IGRA: interferon gamma release assay.",
"     <br>",
"      * These features tend to be characteristic of the respective diseases, but do not occur in every case. For example, a person who has never smoked may develop COPD (especially in the developing world, where other risk factors may be more important than cigarette smoking); asthma may develop in adult and even elderly patients.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted&nbsp;with permission from the Global Initiative for Chronic Obstructive Pulmonary Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: Revised 2011. Global Initiative for Chronic Obstructive Lung Disease (GOLD), www.goldcopd.org (Accessed on August 10, 2012).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13533=[""].join("\n");
var outline_f13_13_13533=null;
var title_f13_13_13534="Trauma secondary survey";
var content_f13_13_13534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65952&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Secondary survey physical examination in the pediatric trauma patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Head",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate face and scalp",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Eye examination",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Visual acuity (if alert)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Pupillary size",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Hemorrhage (conjunctiva, fundi)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Penetrating injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Contact lenses (remove if indicated)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Ocular entrapment",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Periorbital ecchymosis (Raccoon eyes)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Ear examination",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Hemotympanum, bleeding, perforation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Retro-auricular ecchymosis (Battle's sign)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Midface examination",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Inspect for nasal swelling, deformity, bleeding, or clear rhinorrhea",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Inspect for oral trauma, malocclusion, intraoral lacerations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Palpate maxilla for evidence of LeFort fracture (palatal instability with anterior to posterior pressure on the upper teeth)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Cervical spine and neck",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          If maxillofacial/head trauma sustained, presume unstable cervical spine injury and immobilize neck until c-spine adequately evaluated",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate neck",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Tracheal deviation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Distended neck veins",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          C-spine tenderness",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Subcutaneous emphysema",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Crepitus over larynx (concerning for laryngeal fracture)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Carotid artery bruits",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Active range of motion (in awake, cooperative patient without distracting injuries)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Penetrating neck injury",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Inspect to determine if injury may be through the platysma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Chest",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate chest, including the clavicle, ribs, and sternum",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Open pneumothorax/large flail segment",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Crepitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Tenderness/bony deformity",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Auscultate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Breath sounds",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Heart sounds",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Abdomen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate abdomen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Seat belt sign/bruises (Cullen's sign)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Distention",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Focal tenderness",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Peritoneal signs",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Masses",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Auscultate for bowel sounds",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Perineum/rectum/vagina",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspection",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Contusions/lacerations/hematomas",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Males-urethral bleeding",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Females-vaginal bleeding",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Rectal examination",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          May be performed at the end of spinal examination when the body is already turned onto the side",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Assess for blood in bowel lumen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Sphincter tone",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Males (teenage/adult)--palpate for high-riding prostate",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Muskuloskeletal",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate extremities",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Identify fractures/dislocations",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Assess pulses for presence and strength",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect and palpate pelvis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Pain on palpation of pelvic ring",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Mobility of pelvis with anterior-to-posterior pressure with heels of hands on both anterior iliac spines",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Logroll patient to inspect and palpate back",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Examine for step-offs or focal tenderness",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Inspect under the axillae",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Neurologic",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist1_start\">",
"          Comprehensive neurological examination",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Re-evaluation of patient's level of consiousness",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Re-evaluation of patient's pupillary size",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Motor evaluation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"sublist2\">",
"          Sensory evaluation",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     1. American College of Surgeons Committee on Trauma. Advanced Trauma Life Support for Doctors, 8th ed. Chicago, IL: American College of Surgeons; 2008.",
"     <br>",
"      2. Jaffe D, Wesson D. Emergency management of blunt trauma in children.&nbsp;N Engl J Med&nbsp;1991; 324:1477-1483.",
"      <br>",
"       3. Waltzman, ML, Mooney, DP. Major Trauma. In: Fleisher, GR, Ludwig, S, Henretig, FM, eds. Textbook of Pediatric Emergency Medicine. 5th ed. Philadelphia, PA Lippincott Williams &amp; Wilkins; 2006.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13534=[""].join("\n");
var outline_f13_13_13534=null;
var title_f13_13_13535="Antimicrob activity abx A";
var content_f13_13_13535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54268%7EPC%2F70073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54268%7EPC%2F70073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial activity of topical antibiotics used for external otitis: Part A",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Quinolones",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Tetracycline",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"1\">",
"        Sulfonamides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Ciprofloxacin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Ofloxacin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tetracycline",
"       </td>",
"       <td class=\"subtitle2\">",
"        Oxytetracycline",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sulfacetamide",
"       </td>",
"       <td class=\"subtitle2\">",
"        Sulfisoxazole",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Gram-positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corynebacterium diphtheriae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus epidermidis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pneumoniae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pyogenes (group A beta-hemolytic)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\" rowspan=\"1\">",
"        Gram-negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citrobacter sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter aerogenes",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemophilus influenzae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella pneumoniae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antimicrobial activity of topical antibiotics used for external otitis: Part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Organism",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Aminoglycosides",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Neomycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Gentamicin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Tobramycin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Bacitracin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Chloramphenicol",
"       </td>",
"       <td class=\"subtitle2\">",
"        Gramicidin",
"       </td>",
"       <td class=\"subtitle2\">",
"        Polymyxin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Gram positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Corynebacterium diphtheriae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus epidermidis",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pneumoniae",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Streptococcus pyogenes (group A beta-hemolytic)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Gram negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bacteroides fragilis",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Citrobacter sp",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter aerogenes",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enterobacter sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Escherichia coli",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haemophilus influenzae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella pneumoniae",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Klebsiella sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Proteus sp",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pseudomonas aeruginosa",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &bull;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Bojrab DI, Bruderly T, Abdulrazzak Y, Otolaryngol Clin North Am 1996; 29:761.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_13_13535=[""].join("\n");
var outline_f13_13_13535=null;
